The global acute myeloid leukemia (AML) market was valued at USD 4.35 billion in 2025. It is estimated at USD 4.90 billion in 2026 and is expected to reach USD 11.81 billion by 2036, growing at a CAGR of 9.2% over the 2026-2036 forecast period. This report assesses epidemiology, molecular subtypes, treatment pathways, diagnostics and measurable residual disease (MRD) testing, the pipeline, pricing and reimbursement, regulation, and competition.
The study covers drugs used to treat AML across induction, consolidation, maintenance, and relapsed or refractory settings. It includes targeted therapy (menin inhibitors, the BCL-2 inhibitor venetoclax, FLT3 and IDH inhibitors, and hedgehog pathway inhibitors), injectable and oral hypomethylating agents, cytotoxic chemotherapy such as cytarabine, anthracyclines, and liposomal formulations, antibody-drug conjugates and other immunotherapies, cell and gene therapy, and supportive agents.
According to the National Cancer Institute's SEER program, AML remains a disease of older adults with poor outcomes: the median age at diagnosis is 70 years, about 62% of cases occur at age 65 or older, and five-year relative survival stands at 33.4%, with an estimated 22,720 new U.S. cases and 11,500 U.S. deaths expected in 2026. Worldwide, the International Agency for Research on Cancer (IARC) recorded 495,113 new leukemia cases in 2022, nearly half of them in Asia. Spending is led by venetoclax-based therapy: AbbVie reported USD 2.79 billion in 2025 worldwide sales of Venclexta, a figure that also covers CLL.
The small patient population limits revenue per product, especially when a drug is confined to a relapsed molecular subgroup of a few thousand patients a year. Short response durations and early deaths cut time on therapy, cytarabine, anthracyclines, azacitidine, and decitabine are all generic, so the backbone of most regimens earns little, and limited molecular testing and transplant capacity in Asia, Africa, and Latin America restrict use of targeted drugs where most cases occur. Key challenges include drug sequencing and resistance, toxicity in frail patients, payer scrutiny of costly drugs with modest response rates, and competition for trial patients.
The largest opportunity is the move of menin inhibitors into frontline combinations: the Phase 3 KOMET-017 study of ziftomenib in newly diagnosed patients has enrolled its first patient, and revumenib is being studied as a triplet with azacitidine and venetoclax in untreated patients with NPM1 or KMT2A alterations. Maintenance therapy and MRD-guided treatment, all-oral regimens that can be given in outpatient settings, and emerging markets where diagnostics and reimbursement are expanding offer further growth. Key trends include adding branded targeted agents to a low-cost generic backbone, the shift of care from inpatient wards to community and home settings, the use of molecular and MRD testing as core treatment infrastructure, and partnerships between specialist developers and regional commercial partners.
By therapy class, the report covers targeted therapy, hypomethylating agents, chemotherapy, immunotherapy & antibody-drug conjugates, cell & gene therapy, and supportive care & adjunct therapy. Targeted therapy is expected to hold the largest share in 2026, as it includes venetoclax, the anchor of lower-intensity treatment, along with FLT3 inhibitors, IDH1 and IDH2 inhibitors, and the new menin inhibitor class, all of which are branded and priced well above the generic backbone. Within targeted therapy, menin inhibitors are expected to grow at the highest CAGR, supported by the two recent U.S. approvals and the advance of both agents into frontline combination trials. Generic hypomethylating agents and chemotherapy carry large volumes but modest revenue.
The mutation target analysis covers mutation-agnostic & broad-spectrum regimens, NPM1-mutated, FLT3-mutated, IDH-mutated, KMT2A-rearranged, TP53-mutated & adverse-risk disease, and other subtypes. Mutation-agnostic and broad-spectrum regimens are expected to account for the largest share in 2026, as venetoclax-based combinations are given to unfit newly diagnosed patients regardless of genotype and chemotherapy is chosen by fitness rather than mutation. NPM1-mutated disease is expected to grow at the highest CAGR, as both approved menin inhibitors carry NPM1 indications and Syndax estimates about 4,500 U.S. patients with relapsed or refractory NPM1-mutated AML each year, with frontline use set to widen this pool.
By line of therapy, the report covers frontline induction & consolidation, maintenance therapy, and relapsed or refractory therapy. Frontline treatment is expected to hold the largest share in 2026, because every newly diagnosed patient receives first-line therapy while only a portion survive to later lines. Maintenance therapy is expected to grow at the highest CAGR, building on the survival benefit already shown by oral hypomethylating maintenance after remission and the testing of targeted drugs after remission and after transplant, with MRD results used to identify patients at highest risk of relapse. New drugs still win first approval in the relapsed or refractory setting.
By patient fitness, the market is divided into patients ineligible and eligible for intensive chemotherapy. Patients ineligible for intensive chemotherapy are expected to account for the largest share in 2026, as most patients are older and have heart, kidney, or performance status limits that rule out cytarabine and anthracycline induction, and instead receive venetoclax with azacitidine, decitabine, or low-dose cytarabine. Patients eligible for intensive chemotherapy are expected to grow at the highest CAGR, as targeted drugs are added to intensive induction and consolidation, as FLT3 inhibitors have already done, and as post-transplant maintenance becomes routine in younger patients.
By route of administration, the report covers oral, intravenous, and subcutaneous products. Oral therapy is expected to hold the largest share in 2026 and to grow at the highest CAGR, since almost every branded drug launched over the past decade is a pill, including venetoclax, FLT3 and IDH inhibitors, both menin inhibitors, and oral hypomethylating products combining decitabine or azacitidine with a cytidine deaminase inhibitor. Oral treatment also suits an older population that tolerates outpatient care better than long hospital stays.
By treatment setting, the report covers outpatient & ambulatory care, inpatient hospital care, and home-based care. Outpatient and ambulatory care is expected to lead in 2026, as venetoclax plus a hypomethylating agent can be given in clinics with transfusion and infection support, together with oral targeted drugs. Home-based care is expected to grow at the highest CAGR, supported by all-oral regimens, specialty pharmacy dispensing, remote toxicity monitoring, telehealth follow-up, and the preference of older patients to stay at home.
The end user analysis includes hospitals & academic cancer centers, specialty hematology & community oncology practices, transplantation centers, specialty pharmacies, and others. Hospitals and academic cancer centers are expected to hold the largest share in 2026, as AML usually presents as an emergency that needs rapid cytogenetic and molecular workup and induction-phase support. Specialty hematology and community oncology practices are expected to grow at the highest CAGR, as oral, lower-intensity regimens can be given closer to home and reference laboratories now return NPM1, KMT2A, FLT3, and IDH results to community prescribers.
North America is expected to hold the largest share of the market in 2026, owing to early regulatory access, broad molecular testing, concentrated transplant capacity, and the highest spending per patient. Both menin inhibitors launched first in the U.S. Europe is expected to rank second, supported by strong academic hematology networks, cooperative trial groups, and transplant capacity, although health technology assessment bodies compare new drugs with a low-cost generic backbone, which slows uptake and makes managed-entry agreements common. Germany, the U.K., France, Italy, and Spain account for most regional value.
Asia-Pacific is expected to grow at the highest CAGR during the forecast period, as it carries the largest disease burden, with IARC data showing nearly half of global leukemia cases occurring in Asia. Growth is supported by expanding molecular testing, the listing of targeted drugs in national reimbursement schemes and volume-based procurement, and more transplant capacity; Japan is the most developed market, while China pairs very large patient numbers with fast domestic development of menin, FLT3, and BCL-2 inhibitors. In Latin America, Brazil leads, followed by Mexico, Argentina, and Colombia, with diagnostic gaps as the main barrier, while in the Middle East & Africa, Gulf states, Israel, and Turkey adopt new drugs relatively quickly but much of Sub-Saharan Africa lacks basic diagnostic capacity.
The market is moderately consolidated, with large drug makers defending established mechanisms and specialist companies launching first-in-class drugs, often through regional partnerships. AbbVie, with Roche, holds venetoclax; Astellas, Novartis, and Daiichi Sankyo hold FLT3 inhibitors; Servier and Rigel hold IDH inhibitors; Bristol Myers Squibb, Otsuka, and Taiho hold oral hypomethylating products; Pfizer markets an antibody-drug conjugate and Jazz a liposomal chemotherapy; and Syndax, Kura Oncology, and Kyowa Kirin market the menin inhibitors. Johnson & Johnson and Sumitomo Pharma are developing further menin inhibitors, while Teva, Sandoz, Dr. Reddy's, and Hikma supply generic backbone drugs.
Key companies profiled in the report include AbbVie Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Astellas Pharma Inc. (Japan), Novartis AG (Switzerland), Daiichi Sankyo Company, Limited (Japan), Servier Laboratories (France), Bristol-Myers Squibb Company (U.S.), Pfizer Inc. (U.S.), Jazz Pharmaceuticals plc (Ireland), Syndax Pharmaceuticals, Inc. (U.S.), Kura Oncology, Inc. (U.S.), Kyowa Kirin Co., Ltd. (Japan), Otsuka Pharmaceutical Co., Ltd. (Japan), Taiho Pharmaceutical Co., Ltd. (Japan), Rigel Pharmaceuticals, Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sandoz Group AG (Switzerland), Dr. Reddy's Laboratories Ltd. (India), Hikma Pharmaceuticals PLC (U.K.), Johnson & Johnson (U.S.), Sumitomo Pharma Co., Ltd. (Japan), Aptose Biosciences Inc. (Canada), and Immune-Onc Therapeutics, Inc. (U.S.).
The study covers drugs used to treat AML across induction, consolidation, maintenance, and relapsed or refractory settings. It includes targeted therapy (menin inhibitors, the BCL-2 inhibitor venetoclax, FLT3 and IDH inhibitors, and hedgehog pathway inhibitors), injectable and oral hypomethylating agents, cytotoxic chemotherapy such as cytarabine, anthracyclines, and liposomal formulations, antibody-drug conjugates and other immunotherapies, cell and gene therapy, and supportive agents.
According to the National Cancer Institute's SEER program, AML remains a disease of older adults with poor outcomes: the median age at diagnosis is 70 years, about 62% of cases occur at age 65 or older, and five-year relative survival stands at 33.4%, with an estimated 22,720 new U.S. cases and 11,500 U.S. deaths expected in 2026. Worldwide, the International Agency for Research on Cancer (IARC) recorded 495,113 new leukemia cases in 2022, nearly half of them in Asia. Spending is led by venetoclax-based therapy: AbbVie reported USD 2.79 billion in 2025 worldwide sales of Venclexta, a figure that also covers CLL.
Market Dynamics
The arrival of menin inhibitors is the most important growth driver: the U.S. FDA approved ziftomenib (KOMZIFTI) from Kura Oncology and Kyowa Kirin on 13 November 2025, following Syndax's revumenib (Revuforj), giving the market two approved agents in the class within a year. Venetoclax combined with azacitidine or low-dose cytarabine is now the standard for patients too frail for intensive chemotherapy and forms the base onto which new drugs are added. An aging population, wider sequencing at diagnosis, and regulators' readiness to approve on single-arm data add further support.The small patient population limits revenue per product, especially when a drug is confined to a relapsed molecular subgroup of a few thousand patients a year. Short response durations and early deaths cut time on therapy, cytarabine, anthracyclines, azacitidine, and decitabine are all generic, so the backbone of most regimens earns little, and limited molecular testing and transplant capacity in Asia, Africa, and Latin America restrict use of targeted drugs where most cases occur. Key challenges include drug sequencing and resistance, toxicity in frail patients, payer scrutiny of costly drugs with modest response rates, and competition for trial patients.
The largest opportunity is the move of menin inhibitors into frontline combinations: the Phase 3 KOMET-017 study of ziftomenib in newly diagnosed patients has enrolled its first patient, and revumenib is being studied as a triplet with azacitidine and venetoclax in untreated patients with NPM1 or KMT2A alterations. Maintenance therapy and MRD-guided treatment, all-oral regimens that can be given in outpatient settings, and emerging markets where diagnostics and reimbursement are expanding offer further growth. Key trends include adding branded targeted agents to a low-cost generic backbone, the shift of care from inpatient wards to community and home settings, the use of molecular and MRD testing as core treatment infrastructure, and partnerships between specialist developers and regional commercial partners.
Segment Analysis
The report analyzes the market by therapy class, mutation target, line of therapy, patient fitness, route of administration, treatment setting, end user, and geography, helping stakeholders identify where treatment value is moving.By therapy class, the report covers targeted therapy, hypomethylating agents, chemotherapy, immunotherapy & antibody-drug conjugates, cell & gene therapy, and supportive care & adjunct therapy. Targeted therapy is expected to hold the largest share in 2026, as it includes venetoclax, the anchor of lower-intensity treatment, along with FLT3 inhibitors, IDH1 and IDH2 inhibitors, and the new menin inhibitor class, all of which are branded and priced well above the generic backbone. Within targeted therapy, menin inhibitors are expected to grow at the highest CAGR, supported by the two recent U.S. approvals and the advance of both agents into frontline combination trials. Generic hypomethylating agents and chemotherapy carry large volumes but modest revenue.
The mutation target analysis covers mutation-agnostic & broad-spectrum regimens, NPM1-mutated, FLT3-mutated, IDH-mutated, KMT2A-rearranged, TP53-mutated & adverse-risk disease, and other subtypes. Mutation-agnostic and broad-spectrum regimens are expected to account for the largest share in 2026, as venetoclax-based combinations are given to unfit newly diagnosed patients regardless of genotype and chemotherapy is chosen by fitness rather than mutation. NPM1-mutated disease is expected to grow at the highest CAGR, as both approved menin inhibitors carry NPM1 indications and Syndax estimates about 4,500 U.S. patients with relapsed or refractory NPM1-mutated AML each year, with frontline use set to widen this pool.
By line of therapy, the report covers frontline induction & consolidation, maintenance therapy, and relapsed or refractory therapy. Frontline treatment is expected to hold the largest share in 2026, because every newly diagnosed patient receives first-line therapy while only a portion survive to later lines. Maintenance therapy is expected to grow at the highest CAGR, building on the survival benefit already shown by oral hypomethylating maintenance after remission and the testing of targeted drugs after remission and after transplant, with MRD results used to identify patients at highest risk of relapse. New drugs still win first approval in the relapsed or refractory setting.
By patient fitness, the market is divided into patients ineligible and eligible for intensive chemotherapy. Patients ineligible for intensive chemotherapy are expected to account for the largest share in 2026, as most patients are older and have heart, kidney, or performance status limits that rule out cytarabine and anthracycline induction, and instead receive venetoclax with azacitidine, decitabine, or low-dose cytarabine. Patients eligible for intensive chemotherapy are expected to grow at the highest CAGR, as targeted drugs are added to intensive induction and consolidation, as FLT3 inhibitors have already done, and as post-transplant maintenance becomes routine in younger patients.
By route of administration, the report covers oral, intravenous, and subcutaneous products. Oral therapy is expected to hold the largest share in 2026 and to grow at the highest CAGR, since almost every branded drug launched over the past decade is a pill, including venetoclax, FLT3 and IDH inhibitors, both menin inhibitors, and oral hypomethylating products combining decitabine or azacitidine with a cytidine deaminase inhibitor. Oral treatment also suits an older population that tolerates outpatient care better than long hospital stays.
By treatment setting, the report covers outpatient & ambulatory care, inpatient hospital care, and home-based care. Outpatient and ambulatory care is expected to lead in 2026, as venetoclax plus a hypomethylating agent can be given in clinics with transfusion and infection support, together with oral targeted drugs. Home-based care is expected to grow at the highest CAGR, supported by all-oral regimens, specialty pharmacy dispensing, remote toxicity monitoring, telehealth follow-up, and the preference of older patients to stay at home.
The end user analysis includes hospitals & academic cancer centers, specialty hematology & community oncology practices, transplantation centers, specialty pharmacies, and others. Hospitals and academic cancer centers are expected to hold the largest share in 2026, as AML usually presents as an emergency that needs rapid cytogenetic and molecular workup and induction-phase support. Specialty hematology and community oncology practices are expected to grow at the highest CAGR, as oral, lower-intensity regimens can be given closer to home and reference laboratories now return NPM1, KMT2A, FLT3, and IDH results to community prescribers.
Regional Analysis
The report covers North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, with analysis of 22 countries, the Nordic countries, Australia & New Zealand, Southeast Asia, and four rest-of-region groups. It considers disease burden, testing and transplant capacity, approval timing, and reimbursement.North America is expected to hold the largest share of the market in 2026, owing to early regulatory access, broad molecular testing, concentrated transplant capacity, and the highest spending per patient. Both menin inhibitors launched first in the U.S. Europe is expected to rank second, supported by strong academic hematology networks, cooperative trial groups, and transplant capacity, although health technology assessment bodies compare new drugs with a low-cost generic backbone, which slows uptake and makes managed-entry agreements common. Germany, the U.K., France, Italy, and Spain account for most regional value.
Asia-Pacific is expected to grow at the highest CAGR during the forecast period, as it carries the largest disease burden, with IARC data showing nearly half of global leukemia cases occurring in Asia. Growth is supported by expanding molecular testing, the listing of targeted drugs in national reimbursement schemes and volume-based procurement, and more transplant capacity; Japan is the most developed market, while China pairs very large patient numbers with fast domestic development of menin, FLT3, and BCL-2 inhibitors. In Latin America, Brazil leads, followed by Mexico, Argentina, and Colombia, with diagnostic gaps as the main barrier, while in the Middle East & Africa, Gulf states, Israel, and Turkey adopt new drugs relatively quickly but much of Sub-Saharan Africa lacks basic diagnostic capacity.
Competitive Landscape
The report reviews key growth strategies, competitive benchmarking, the competitive dashboard, strategic developments (regulatory approvals and label expansions, launches, partnerships and licensing, acquisitions, trial readouts, and companion diagnostic collaborations), and 2025 market share/rank analysis, with company profiles covering business overview, financials, product portfolio, developments, and SWOT analysis.The market is moderately consolidated, with large drug makers defending established mechanisms and specialist companies launching first-in-class drugs, often through regional partnerships. AbbVie, with Roche, holds venetoclax; Astellas, Novartis, and Daiichi Sankyo hold FLT3 inhibitors; Servier and Rigel hold IDH inhibitors; Bristol Myers Squibb, Otsuka, and Taiho hold oral hypomethylating products; Pfizer markets an antibody-drug conjugate and Jazz a liposomal chemotherapy; and Syndax, Kura Oncology, and Kyowa Kirin market the menin inhibitors. Johnson & Johnson and Sumitomo Pharma are developing further menin inhibitors, while Teva, Sandoz, Dr. Reddy's, and Hikma supply generic backbone drugs.
Key companies profiled in the report include AbbVie Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Astellas Pharma Inc. (Japan), Novartis AG (Switzerland), Daiichi Sankyo Company, Limited (Japan), Servier Laboratories (France), Bristol-Myers Squibb Company (U.S.), Pfizer Inc. (U.S.), Jazz Pharmaceuticals plc (Ireland), Syndax Pharmaceuticals, Inc. (U.S.), Kura Oncology, Inc. (U.S.), Kyowa Kirin Co., Ltd. (Japan), Otsuka Pharmaceutical Co., Ltd. (Japan), Taiho Pharmaceutical Co., Ltd. (Japan), Rigel Pharmaceuticals, Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sandoz Group AG (Switzerland), Dr. Reddy's Laboratories Ltd. (India), Hikma Pharmaceuticals PLC (U.K.), Johnson & Johnson (U.S.), Sumitomo Pharma Co., Ltd. (Japan), Aptose Biosciences Inc. (Canada), and Immune-Onc Therapeutics, Inc. (U.S.).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global acute myeloid leukemia market through 2036.
- Explains how menin inhibitors, venetoclax-based regimens, and molecular testing are reshaping AML treatment and spending.
- Assesses the impact of small patient pools, short treatment duration, generic backbones, and payer scrutiny on market value.
- Identifies high-growth opportunities across therapy class, mutation target, line of therapy, patient fitness, route, setting, end user, and region.
- Tracks the pipeline across menin, FLT3, IDH, CD123, immunotherapy, and cell therapy programs, including frontline and maintenance trials.
- Benchmarks leading drug makers, specialist developers, and generic suppliers on portfolios, partnerships, and strategy.
- Supports portfolio, development, access, and licensing decisions for drug developers and investors.
Key Questions Answered
- How large is the global acute myeloid leukemia market today, and how will it grow through 2036?
- How will the move of menin inhibitors into frontline combinations change the size and structure of the market?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- How do the generic chemotherapy and hypomethylating backbone affect pricing and reimbursement of new drugs?
- Which therapy classes, mutation targets, lines of therapy, and care settings will grow the fastest?
- How are molecular diagnostics and MRD testing changing treatment selection and duration?
- Which regions and countries offer the most attractive opportunities as testing and reimbursement expand?
- Who are the leading companies in the market, and how do they compare?
- What approvals, licensing deals, and trial readouts are shaping competition?
Table of Contents
1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency and Limitations
1.3.1. Currency
1.3.2. Limitations
1.4. Scope of the Study
1.5. Key Stakeholders
1.2. Market Ecosystem
1.3. Currency and Limitations
1.3.1. Currency
1.3.2. Limitations
1.4. Scope of the Study
1.5. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Data Collection & Validation Process
2.2.1. Secondary Research
2.2.2. Primary Research & Validation
2.2.2.1. Primary Interviews with Haematologists and Transplant Programme Directors
2.2.2.2. Country-Level Incidence, Diagnostic Access and Reimbursement Analysis
2.3. Market Estimation
2.3.1. Bottom-Up Approach (Incident and Treated Population x Mutation Prevalence x Annual Cost of Therapy)
2.3.2. Top-Down Approach (Company Reported Sales and AML-Indicated Share)
2.3.3. Forecast Methodology (Treatment Penetration, Line Progression and Net Price Trajectory)
2.4. Data Triangulation
2.5. Assumptions
2.2. Data Collection & Validation Process
2.2.1. Secondary Research
2.2.2. Primary Research & Validation
2.2.2.1. Primary Interviews with Haematologists and Transplant Programme Directors
2.2.2.2. Country-Level Incidence, Diagnostic Access and Reimbursement Analysis
2.3. Market Estimation
2.3.1. Bottom-Up Approach (Incident and Treated Population x Mutation Prevalence x Annual Cost of Therapy)
2.3.2. Top-Down Approach (Company Reported Sales and AML-Indicated Share)
2.3.3. Forecast Methodology (Treatment Penetration, Line Progression and Net Price Trajectory)
2.4. Data Triangulation
2.5. Assumptions
3. Executive Summary
3.1. Key Findings
3.2. Market Snapshot
3.3. Strategic Insights
3.4. Analyst Perspective
3.2. Market Snapshot
3.3. Strategic Insights
3.4. Analyst Perspective
4. Market Insights
4.1. Industry Overview
4.2. Epidemiology and Disease Burden
4.2.1. Global and Regional Leukaemia Incidence and Mortality
4.2.2. Acute Myeloid Leukemia Incidence by Age Group
4.2.3. Survival Outcomes and Mortality Trends
4.2.4. Paediatric and Adolescent Acute Myeloid Leukemia
4.2.5. Secondary and Therapy-Related Acute Myeloid Leukemia
4.2.6. Diagnosed versus Treated Population Analysis
4.3. Molecular and Cytogenetic Landscape
4.3.1. Prevalence of NPM1 Mutations
4.3.2. Prevalence of FLT3-ITD and FLT3-TKD Mutations
4.3.3. Prevalence of IDH1 and IDH2 Mutations
4.3.4. KMT2A Rearrangements and NUP98 Fusions
4.3.5. TP53 Mutations and Complex Karyotype
4.3.6. Co-Mutation Patterns and Clonal Evolution
4.3.7. European LeukemiaNet and WHO Classification Risk Stratification
4.4. Treatment Pathway Analysis
4.4.1. Intensive Induction and Consolidation
4.4.2. Lower-Intensity Hypomethylating and Venetoclax-Based Regimens
4.4.3. Mutation-Directed Targeted Therapy
4.4.4. Allogeneic Haematopoietic Cell Transplantation
4.4.5. Post-Remission and Post-Transplant Maintenance
4.4.6. Relapsed and Refractory Treatment Sequencing
4.4.7. Supportive and Palliative Care
4.5. Diagnostics and Measurable Residual Disease Landscape
4.5.1. Cytogenetics and Fluorescence In Situ Hybridisation
4.5.2. Targeted Next-Generation Sequencing Panels
4.5.3. Polymerase Chain Reaction-Based Mutation Assays
4.5.4. Multiparameter Flow Cytometry
4.5.5. Measurable Residual Disease Quantification and Treatment Decisions
4.5.6. Companion Diagnostic Approvals and Laboratory Turnaround Times
4.6. Technology and Modality Landscape
4.6.1. Menin-KMT2A Interaction Inhibition
4.6.2. BCL-2 and Apoptotic Pathway Inhibition
4.6.3. Tyrosine Kinase Inhibition
4.6.4. Isocitrate Dehydrogenase Inhibition and Differentiation Therapy
4.6.5. Epigenetic and Hypomethylating Mechanisms
4.6.6. Antibody-Drug Conjugates and Bispecific Antibodies
4.6.7. CAR-T, NK Cell and Allogeneic Cell Therapy Approaches
4.6.8. Oral Formulation and Bioavailability Technologies
4.7. Clinical Pipeline Analysis
4.7.1. Frontline Menin Inhibitor Combination Programmes
4.7.2. Triplet Regimens with Hypomethylating Agents and Venetoclax
4.7.3. Next-Generation FLT3 and IDH Inhibitors
4.7.4. TP53-Mutated and Adverse-Risk Disease Programmes
4.7.5. CD123, CD33 and Immunotherapeutic Targets
4.7.6. Maintenance and Measurable Residual Disease-Guided Trial Designs
4.8. Pricing and Reimbursement Analysis
4.8.1. Annual Cost of Therapy by Regimen Class
4.8.2. Impact of Backbone Genericisation on Regimen Economics
4.8.3. U.S. Payer Prior Authorisation and Specialty Pharmacy Adjudication
4.8.4. European Health Technology Assessment and Managed-Entry Agreements
4.8.5. Volume-Based Procurement and National Reimbursement Listing in Asia-Pacific
4.8.6. Orphan Drug Pricing and Access Programmes
4.9. Patent Expiry and Generic Outlook
4.9.1. Genericised Cytotoxics and Hypomethylating Agents
4.9.2. Exclusivity Timelines for Branded Targeted Agents
4.10. Regulatory Landscape
4.10.1. Orphan Drug and Accelerated Approval Pathways
4.10.2. Breakthrough Therapy and Priority Review Designations
4.10.3. Single-Arm Trial Acceptance and Confirmatory Evidence Requirements
4.10.4. Companion Diagnostic Co-Approval Requirements
4.10.5. Regional Regulatory Divergence and Reliance Pathways
4.11. Treatment Capacity and Health System Readiness
4.11.1. Transplantation Centre and Donor Registry Capacity
4.11.2. Molecular Diagnostic Infrastructure by Region
4.11.3. Haematology Workforce Availability
4.12. Value Chain Analysis
4.13. Supply Chain and Manufacturing Analysis
4.13.1. Active Pharmaceutical Ingredient Sourcing
4.13.2. Sterile Injectable and Oral Solid Dose Manufacturing
4.13.3. Cold Chain and Specialty Distribution
4.14. Patent Analysis
4.15. Investment, Partnership and Licensing Landscape
4.16. Porter's Five Forces Analysis
4.17. Industry Attractiveness Assessment
4.2. Epidemiology and Disease Burden
4.2.1. Global and Regional Leukaemia Incidence and Mortality
4.2.2. Acute Myeloid Leukemia Incidence by Age Group
4.2.3. Survival Outcomes and Mortality Trends
4.2.4. Paediatric and Adolescent Acute Myeloid Leukemia
4.2.5. Secondary and Therapy-Related Acute Myeloid Leukemia
4.2.6. Diagnosed versus Treated Population Analysis
4.3. Molecular and Cytogenetic Landscape
4.3.1. Prevalence of NPM1 Mutations
4.3.2. Prevalence of FLT3-ITD and FLT3-TKD Mutations
4.3.3. Prevalence of IDH1 and IDH2 Mutations
4.3.4. KMT2A Rearrangements and NUP98 Fusions
4.3.5. TP53 Mutations and Complex Karyotype
4.3.6. Co-Mutation Patterns and Clonal Evolution
4.3.7. European LeukemiaNet and WHO Classification Risk Stratification
4.4. Treatment Pathway Analysis
4.4.1. Intensive Induction and Consolidation
4.4.2. Lower-Intensity Hypomethylating and Venetoclax-Based Regimens
4.4.3. Mutation-Directed Targeted Therapy
4.4.4. Allogeneic Haematopoietic Cell Transplantation
4.4.5. Post-Remission and Post-Transplant Maintenance
4.4.6. Relapsed and Refractory Treatment Sequencing
4.4.7. Supportive and Palliative Care
4.5. Diagnostics and Measurable Residual Disease Landscape
4.5.1. Cytogenetics and Fluorescence In Situ Hybridisation
4.5.2. Targeted Next-Generation Sequencing Panels
4.5.3. Polymerase Chain Reaction-Based Mutation Assays
4.5.4. Multiparameter Flow Cytometry
4.5.5. Measurable Residual Disease Quantification and Treatment Decisions
4.5.6. Companion Diagnostic Approvals and Laboratory Turnaround Times
4.6. Technology and Modality Landscape
4.6.1. Menin-KMT2A Interaction Inhibition
4.6.2. BCL-2 and Apoptotic Pathway Inhibition
4.6.3. Tyrosine Kinase Inhibition
4.6.4. Isocitrate Dehydrogenase Inhibition and Differentiation Therapy
4.6.5. Epigenetic and Hypomethylating Mechanisms
4.6.6. Antibody-Drug Conjugates and Bispecific Antibodies
4.6.7. CAR-T, NK Cell and Allogeneic Cell Therapy Approaches
4.6.8. Oral Formulation and Bioavailability Technologies
4.7. Clinical Pipeline Analysis
4.7.1. Frontline Menin Inhibitor Combination Programmes
4.7.2. Triplet Regimens with Hypomethylating Agents and Venetoclax
4.7.3. Next-Generation FLT3 and IDH Inhibitors
4.7.4. TP53-Mutated and Adverse-Risk Disease Programmes
4.7.5. CD123, CD33 and Immunotherapeutic Targets
4.7.6. Maintenance and Measurable Residual Disease-Guided Trial Designs
4.8. Pricing and Reimbursement Analysis
4.8.1. Annual Cost of Therapy by Regimen Class
4.8.2. Impact of Backbone Genericisation on Regimen Economics
4.8.3. U.S. Payer Prior Authorisation and Specialty Pharmacy Adjudication
4.8.4. European Health Technology Assessment and Managed-Entry Agreements
4.8.5. Volume-Based Procurement and National Reimbursement Listing in Asia-Pacific
4.8.6. Orphan Drug Pricing and Access Programmes
4.9. Patent Expiry and Generic Outlook
4.9.1. Genericised Cytotoxics and Hypomethylating Agents
4.9.2. Exclusivity Timelines for Branded Targeted Agents
4.10. Regulatory Landscape
4.10.1. Orphan Drug and Accelerated Approval Pathways
4.10.2. Breakthrough Therapy and Priority Review Designations
4.10.3. Single-Arm Trial Acceptance and Confirmatory Evidence Requirements
4.10.4. Companion Diagnostic Co-Approval Requirements
4.10.5. Regional Regulatory Divergence and Reliance Pathways
4.11. Treatment Capacity and Health System Readiness
4.11.1. Transplantation Centre and Donor Registry Capacity
4.11.2. Molecular Diagnostic Infrastructure by Region
4.11.3. Haematology Workforce Availability
4.12. Value Chain Analysis
4.13. Supply Chain and Manufacturing Analysis
4.13.1. Active Pharmaceutical Ingredient Sourcing
4.13.2. Sterile Injectable and Oral Solid Dose Manufacturing
4.13.3. Cold Chain and Specialty Distribution
4.14. Patent Analysis
4.15. Investment, Partnership and Licensing Landscape
4.16. Porter's Five Forces Analysis
4.17. Industry Attractiveness Assessment
5. Market Dynamics
5.1. Drivers
5.1.1. Commercial Establishment of the Menin Inhibitor Class
5.1.2. Entrenchment of Venetoclax-Based Regimens in Unfit Patients
5.1.3. Demographic Profile and Ageing of the Patient Population
5.1.4. Expansion of Molecular Diagnostics and Mutation-Directed Treatment Pathways
5.1.5. Severity of Unmet Need Supporting Accelerated Regulatory Pathways
5.2. Restraints
5.2.1. Small Absolute Patient Population Relative to Development Cost
5.2.2. Short Response Durations and Early Mortality Limiting Treatment Duration
5.2.3. Genericisation of the Chemotherapy and Hypomethylating Backbone
5.2.4. Constrained Access to Molecular Testing and Transplantation Capacity
5.3. Opportunities
5.3.1. Menin Inhibitors in Frontline Combination Regimens
5.3.2. Maintenance Therapy and Measurable Residual Disease-Guided Treatment
5.3.3. Oral and Outpatient-Deliverable Regimens for Elderly and Unfit Patients
5.3.4. Emerging Market Volume as Diagnostics and Reimbursement Expand
5.4. Challenges
5.4.1. Resistance and Sequencing across Overlapping Targeted Classes
5.4.2. Toxicity Management in a Comorbid Elderly Population
5.4.3. Payer Scrutiny of High-Priced Therapy with Modest Response Rates
5.4.4. Trial Recruitment Competition in a Small Molecularly Subset Population
5.5. Key Trends
5.5.1. Layering of Targeted Agents onto a Genericised Backbone
5.5.2. Migration of Treatment from Inpatient to Community and Outpatient Settings
5.5.3. Molecular Diagnostics and Measurable Residual Disease as Treatment Infrastructure
5.5.4. Specialist Haematology Companies Partnering with Regional Commercial Platforms
5.1.1. Commercial Establishment of the Menin Inhibitor Class
5.1.2. Entrenchment of Venetoclax-Based Regimens in Unfit Patients
5.1.3. Demographic Profile and Ageing of the Patient Population
5.1.4. Expansion of Molecular Diagnostics and Mutation-Directed Treatment Pathways
5.1.5. Severity of Unmet Need Supporting Accelerated Regulatory Pathways
5.2. Restraints
5.2.1. Small Absolute Patient Population Relative to Development Cost
5.2.2. Short Response Durations and Early Mortality Limiting Treatment Duration
5.2.3. Genericisation of the Chemotherapy and Hypomethylating Backbone
5.2.4. Constrained Access to Molecular Testing and Transplantation Capacity
5.3. Opportunities
5.3.1. Menin Inhibitors in Frontline Combination Regimens
5.3.2. Maintenance Therapy and Measurable Residual Disease-Guided Treatment
5.3.3. Oral and Outpatient-Deliverable Regimens for Elderly and Unfit Patients
5.3.4. Emerging Market Volume as Diagnostics and Reimbursement Expand
5.4. Challenges
5.4.1. Resistance and Sequencing across Overlapping Targeted Classes
5.4.2. Toxicity Management in a Comorbid Elderly Population
5.4.3. Payer Scrutiny of High-Priced Therapy with Modest Response Rates
5.4.4. Trial Recruitment Competition in a Small Molecularly Subset Population
5.5. Key Trends
5.5.1. Layering of Targeted Agents onto a Genericised Backbone
5.5.2. Migration of Treatment from Inpatient to Community and Outpatient Settings
5.5.3. Molecular Diagnostics and Measurable Residual Disease as Treatment Infrastructure
5.5.4. Specialist Haematology Companies Partnering with Regional Commercial Platforms
6. Acute Myeloid Leukemia Market, by Therapy Class
6.1. Introduction
6.2. Targeted Therapy
6.2.1. Menin Inhibitors
6.2.1.1. Revumenib
6.2.1.2. Ziftomenib
6.2.1.3. Emerging Menin Inhibitors
6.2.2. BCL-2 Inhibitors
6.2.2.1. Venetoclax
6.2.2.2. Next-Generation BCL-2 and MCL-1 Inhibitors
6.2.3. FLT3 Inhibitors
6.2.3.1. Midostaurin
6.2.3.2. Gilteritinib
6.2.3.3. Quizartinib
6.2.3.4. Emerging FLT3 Inhibitors
6.2.4. IDH Inhibitors
6.2.4.1. Ivosidenib (IDH1)
6.2.4.2. Olutasidenib (IDH1)
6.2.4.3. Enasidenib (IDH2)
6.2.5. Hedgehog Pathway Inhibitors
6.2.6. Other Targeted Agents
6.3. Hypomethylating Agents
6.3.1. Injectable Hypomethylating Agents
6.3.1.1. Azacitidine
6.3.1.2. Decitabine
6.3.2. Oral Hypomethylating Agents
6.3.2.1. Oral Azacitidine
6.3.2.2. Decitabine and Cedazuridine
6.4. Chemotherapy
6.4.1. Cytarabine-Based Regimens
6.4.1.1. Standard-Dose Cytarabine
6.4.1.2. High-Dose Cytarabine
6.4.1.3. Low-Dose Cytarabine
6.4.2. Anthracyclines
6.4.2.1. Daunorubicin
6.4.2.2. Idarubicin
6.4.3. Liposomal Chemotherapy Formulations
6.4.4. Hypomethylating-Free Low-Intensity Regimens
6.5. Immunotherapy & Antibody-Drug Conjugates
6.5.1. CD33-Directed Antibody-Drug Conjugates
6.5.2. CD123-Directed Agents
6.5.3. Bispecific T-Cell Engagers
6.5.4. Immune Checkpoint and Macrophage Checkpoint Agents
6.6. Cell & Gene Therapy
6.6.1. Autologous CAR-T Therapy
6.6.2. Allogeneic CAR-T and CAR-NK Therapy
6.6.3. Donor Lymphocyte and Adoptive Cell Approaches
6.7. Supportive Care & Adjunct Therapy
6.2. Targeted Therapy
6.2.1. Menin Inhibitors
6.2.1.1. Revumenib
6.2.1.2. Ziftomenib
6.2.1.3. Emerging Menin Inhibitors
6.2.2. BCL-2 Inhibitors
6.2.2.1. Venetoclax
6.2.2.2. Next-Generation BCL-2 and MCL-1 Inhibitors
6.2.3. FLT3 Inhibitors
6.2.3.1. Midostaurin
6.2.3.2. Gilteritinib
6.2.3.3. Quizartinib
6.2.3.4. Emerging FLT3 Inhibitors
6.2.4. IDH Inhibitors
6.2.4.1. Ivosidenib (IDH1)
6.2.4.2. Olutasidenib (IDH1)
6.2.4.3. Enasidenib (IDH2)
6.2.5. Hedgehog Pathway Inhibitors
6.2.6. Other Targeted Agents
6.3. Hypomethylating Agents
6.3.1. Injectable Hypomethylating Agents
6.3.1.1. Azacitidine
6.3.1.2. Decitabine
6.3.2. Oral Hypomethylating Agents
6.3.2.1. Oral Azacitidine
6.3.2.2. Decitabine and Cedazuridine
6.4. Chemotherapy
6.4.1. Cytarabine-Based Regimens
6.4.1.1. Standard-Dose Cytarabine
6.4.1.2. High-Dose Cytarabine
6.4.1.3. Low-Dose Cytarabine
6.4.2. Anthracyclines
6.4.2.1. Daunorubicin
6.4.2.2. Idarubicin
6.4.3. Liposomal Chemotherapy Formulations
6.4.4. Hypomethylating-Free Low-Intensity Regimens
6.5. Immunotherapy & Antibody-Drug Conjugates
6.5.1. CD33-Directed Antibody-Drug Conjugates
6.5.2. CD123-Directed Agents
6.5.3. Bispecific T-Cell Engagers
6.5.4. Immune Checkpoint and Macrophage Checkpoint Agents
6.6. Cell & Gene Therapy
6.6.1. Autologous CAR-T Therapy
6.6.2. Allogeneic CAR-T and CAR-NK Therapy
6.6.3. Donor Lymphocyte and Adoptive Cell Approaches
6.7. Supportive Care & Adjunct Therapy
7. Acute Myeloid Leukemia Market, by Mutation Target
7.1. Introduction
7.2. Mutation-Agnostic & Broad-Spectrum Regimens
7.3. NPM1-Mutated Disease
7.4. FLT3-Mutated Disease
7.4.1. FLT3-ITD
7.4.2. FLT3-TKD
7.5. IDH-Mutated Disease
7.5.1. IDH1-Mutated
7.5.2. IDH2-Mutated
7.6. KMT2A-Rearranged Disease
7.7. TP53-Mutated & Adverse-Risk Disease
7.8. Other Molecular Subtypes
7.2. Mutation-Agnostic & Broad-Spectrum Regimens
7.3. NPM1-Mutated Disease
7.4. FLT3-Mutated Disease
7.4.1. FLT3-ITD
7.4.2. FLT3-TKD
7.5. IDH-Mutated Disease
7.5.1. IDH1-Mutated
7.5.2. IDH2-Mutated
7.6. KMT2A-Rearranged Disease
7.7. TP53-Mutated & Adverse-Risk Disease
7.8. Other Molecular Subtypes
8. Acute Myeloid Leukemia Market, by Line of Therapy
8.1. Introduction
8.2. Frontline Induction & Consolidation
8.2.1. Intensive Induction
8.2.2. Lower-Intensity Induction
8.2.3. Consolidation Therapy
8.3. Maintenance Therapy
8.3.1. Post-Remission Maintenance
8.3.2. Post-Transplant Maintenance
8.4. Relapsed or Refractory Therapy
8.4.1. First Relapse
8.4.2. Second and Later Relapse
8.4.3. Primary Refractory Disease
8.2. Frontline Induction & Consolidation
8.2.1. Intensive Induction
8.2.2. Lower-Intensity Induction
8.2.3. Consolidation Therapy
8.3. Maintenance Therapy
8.3.1. Post-Remission Maintenance
8.3.2. Post-Transplant Maintenance
8.4. Relapsed or Refractory Therapy
8.4.1. First Relapse
8.4.2. Second and Later Relapse
8.4.3. Primary Refractory Disease
9. Acute Myeloid Leukemia Market, by Patient Fitness
9.1. Introduction
9.2. Patients Ineligible for Intensive Chemotherapy
9.2.1. Age-Based Ineligibility
9.2.2. Comorbidity and Performance Status-Based Ineligibility
9.3. Patients Eligible for Intensive Chemotherapy
9.3.1. Transplant-Eligible Patients
9.3.2. Transplant-Ineligible Patients
9.2. Patients Ineligible for Intensive Chemotherapy
9.2.1. Age-Based Ineligibility
9.2.2. Comorbidity and Performance Status-Based Ineligibility
9.3. Patients Eligible for Intensive Chemotherapy
9.3.1. Transplant-Eligible Patients
9.3.2. Transplant-Ineligible Patients
10. Acute Myeloid Leukemia Market, by Route of Administration
10.1. Introduction
10.2. Oral
10.2.1. Oral Targeted Agents
10.2.2. Oral Hypomethylating Agents
10.3. Intravenous
10.3.1. Cytotoxic Infusion
10.3.2. Antibody and Conjugate Infusion
10.4. Subcutaneous
10.2. Oral
10.2.1. Oral Targeted Agents
10.2.2. Oral Hypomethylating Agents
10.3. Intravenous
10.3.1. Cytotoxic Infusion
10.3.2. Antibody and Conjugate Infusion
10.4. Subcutaneous
11. Acute Myeloid Leukemia Market, by Treatment Setting
11.1. Introduction
11.2. Outpatient & Ambulatory Care
11.3. Inpatient Hospital Care
11.4. Home-Based Care
11.2. Outpatient & Ambulatory Care
11.3. Inpatient Hospital Care
11.4. Home-Based Care
12. Acute Myeloid Leukemia Market, by End User
12.1. Introduction
12.2. Hospitals & Academic Cancer Centers
12.3. Specialty Haematology & Community Oncology Practices
12.4. Transplantation Centers
12.5. Specialty Pharmacies
12.6. Other End Users
12.2. Hospitals & Academic Cancer Centers
12.3. Specialty Haematology & Community Oncology Practices
12.4. Transplantation Centers
12.5. Specialty Pharmacies
12.6. Other End Users
13. Acute Myeloid Leukemia Market, by Geography
13.1. Introduction
13.2. North America
13.2.1. U.S.
13.2.2. Canada
13.3. Europe
13.3.1. Germany
13.3.2. U.K.
13.3.3. France
13.3.4. Italy
13.3.5. Spain
13.3.6. Netherlands
13.3.7. Nordic Countries
13.3.8. Rest of Europe
13.4. Asia-Pacific
13.4.1. China
13.4.2. Japan
13.4.3. India
13.4.4. South Korea
13.4.5. Australia & New Zealand
13.4.6. Southeast Asia
13.4.7. Rest of Asia-Pacific
13.5. Latin America
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Argentina
13.5.4. Colombia
13.5.5. Rest of Latin America
13.6. Middle East & Africa
13.6.1. Saudi Arabia
13.6.2. UAE
13.6.3. Israel
13.6.4. Turkey
13.6.5. South Africa
13.6.6. Egypt
13.6.7. Rest of Middle East & Africa
13.2. North America
13.2.1. U.S.
13.2.2. Canada
13.3. Europe
13.3.1. Germany
13.3.2. U.K.
13.3.3. France
13.3.4. Italy
13.3.5. Spain
13.3.6. Netherlands
13.3.7. Nordic Countries
13.3.8. Rest of Europe
13.4. Asia-Pacific
13.4.1. China
13.4.2. Japan
13.4.3. India
13.4.4. South Korea
13.4.5. Australia & New Zealand
13.4.6. Southeast Asia
13.4.7. Rest of Asia-Pacific
13.5. Latin America
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Argentina
13.5.4. Colombia
13.5.5. Rest of Latin America
13.6. Middle East & Africa
13.6.1. Saudi Arabia
13.6.2. UAE
13.6.3. Israel
13.6.4. Turkey
13.6.5. South Africa
13.6.6. Egypt
13.6.7. Rest of Middle East & Africa
14. Competitive Landscape
14.1. Overview
14.2. Key Growth Strategies
14.3. Competitive Benchmarking
14.4. Competitive Dashboard
14.4.1. Industry Leaders
14.4.2. Market Differentiators
14.4.3. Vanguards
14.4.4. Emerging Companies
14.5. Strategic Developments
14.5.1. Regulatory Approvals and Label Expansions
14.5.2. Product Launches and Commercial Rollouts
14.5.3. Partnerships, Licensing and Co-Development Agreements
14.5.4. Mergers and Acquisitions
14.5.5. Clinical Trial Initiations and Data Readouts
14.5.6. Companion Diagnostic Collaborations
14.6. Market Share/Rank Analysis, by Key Player (2025)
14.2. Key Growth Strategies
14.3. Competitive Benchmarking
14.4. Competitive Dashboard
14.4.1. Industry Leaders
14.4.2. Market Differentiators
14.4.3. Vanguards
14.4.4. Emerging Companies
14.5. Strategic Developments
14.5.1. Regulatory Approvals and Label Expansions
14.5.2. Product Launches and Commercial Rollouts
14.5.3. Partnerships, Licensing and Co-Development Agreements
14.5.4. Mergers and Acquisitions
14.5.5. Clinical Trial Initiations and Data Readouts
14.5.6. Companion Diagnostic Collaborations
14.6. Market Share/Rank Analysis, by Key Player (2025)
15. Company Profiles
(Business Overview, Financial Overview, Product Portfolio, Strategic Developments, SWOT Analysis)
Companies with Marketed Acute Myeloid Leukemia Products
15.1. AbbVie Inc.
15.2. F. Hoffmann-La Roche Ltd
15.3. Astellas Pharma Inc.
15.4. Novartis AG
15.5. Daiichi Sankyo Company, Limited
15.6. Servier Laboratories
15.7. Bristol-Myers Squibb Company
15.8. Pfizer Inc.
15.9. Jazz Pharmaceuticals plc
15.10. Syndax Pharmaceuticals, Inc.
15.11. Kura Oncology, Inc.
15.12. Kyowa Kirin Co., Ltd.
15.13. Otsuka Pharmaceutical Co., Ltd.
15.14. Taiho Pharmaceutical Co., Ltd.
15.15. Rigel Pharmaceuticals, Inc.
Generic and Sterile Injectable Suppliers
15.16. Teva Pharmaceutical Industries Ltd.
15.17. Sandoz Group AG
15.18. Dr. Reddy's Laboratories Ltd.
15.19. Hikma Pharmaceuticals PLC
Clinical-Stage and Emerging Developers
15.20. Johnson & Johnson
15.21. Sumitomo Pharma Co., Ltd.
15.22. Aptose Biosciences Inc.
15.23. Immune-Onc Therapeutics, Inc.
Companies with Marketed Acute Myeloid Leukemia Products
15.1. AbbVie Inc.
15.2. F. Hoffmann-La Roche Ltd
15.3. Astellas Pharma Inc.
15.4. Novartis AG
15.5. Daiichi Sankyo Company, Limited
15.6. Servier Laboratories
15.7. Bristol-Myers Squibb Company
15.8. Pfizer Inc.
15.9. Jazz Pharmaceuticals plc
15.10. Syndax Pharmaceuticals, Inc.
15.11. Kura Oncology, Inc.
15.12. Kyowa Kirin Co., Ltd.
15.13. Otsuka Pharmaceutical Co., Ltd.
15.14. Taiho Pharmaceutical Co., Ltd.
15.15. Rigel Pharmaceuticals, Inc.
Generic and Sterile Injectable Suppliers
15.16. Teva Pharmaceutical Industries Ltd.
15.17. Sandoz Group AG
15.18. Dr. Reddy's Laboratories Ltd.
15.19. Hikma Pharmaceuticals PLC
Clinical-Stage and Emerging Developers
15.20. Johnson & Johnson
15.21. Sumitomo Pharma Co., Ltd.
15.22. Aptose Biosciences Inc.
15.23. Immune-Onc Therapeutics, Inc.
16. Appendix
16.1. Related Reports
16.2. Customization Options
16.2. Customization Options
LIST OF TABLES
Table 1. Global Acute Myeloid Leukemia Market Drivers: Impact Analysis (2026-2036)
Table 2. Global Acute Myeloid Leukemia Market Restraints: Impact Analysis (2026-2036)
Table 3. Global Acute Myeloid Leukemia Market Opportunities: Impact Analysis (2026-2036)
Table 4. Global Acute Myeloid Leukemia Market Challenges: Impact Analysis (2026-2036)
Table 5. Global Leukemia Incidence and Mortality, by Region (IARC, 2022)
Table 6. Acute Myeloid Leukemia Incidence, by Age Group (SEER)
Table 7. Prevalence of Key Molecular Alterations in AML (NPM1, FLT3, IDH1/2, KMT2A, TP53)
Table 8. Approved AML Therapies, by Mechanism, Indication and Companion Diagnostic
Table 9. Selected Late-Stage AML Pipeline Candidates, by Mechanism and Line of Therapy
Table 10. Annual Cost of Therapy, by Regimen Class
Table 11. Exclusivity Timelines for Branded Targeted AML Agents
Table 12. Key Licensing, Partnership and Co-Development Agreements in AML
Table 13. Porter's Five Forces Analysis: Acute Myeloid Leukemia Market
Table 14. Global Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 15. Global Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 16. Acute Myeloid Leukemia Market for Targeted Therapy, by Country/Region, 2024-2036 (USD Million)
Table 17. Acute Myeloid Leukemia Market for Menin Inhibitors, by Country/Region, 2024-2036 (USD Million)
Table 18. Acute Myeloid Leukemia Market for BCL-2 Inhibitors, by Country/Region, 2024-2036 (USD Million)
Table 19. Acute Myeloid Leukemia Market for FLT3 Inhibitors, by Country/Region, 2024-2036 (USD Million)
Table 20. Acute Myeloid Leukemia Market for IDH Inhibitors, by Country/Region, 2024-2036 (USD Million)
Table 21. Acute Myeloid Leukemia Market for Hedgehog Pathway Inhibitors, by Country/Region, 2024-2036 (USD Million)
Table 22. Acute Myeloid Leukemia Market for Other Targeted Agents, by Country/Region, 2024-2036 (USD Million)
Table 23. Global Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 24. Acute Myeloid Leukemia Market for Hypomethylating Agents, by Country/Region, 2024-2036 (USD Million)
Table 25. Acute Myeloid Leukemia Market for Injectable Hypomethylating Agents, by Country/Region, 2024-2036 (USD Million)
Table 26. Acute Myeloid Leukemia Market for Oral Hypomethylating Agents, by Country/Region, 2024-2036 (USD Million)
Table 27. Global Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 28. Acute Myeloid Leukemia Market for Chemotherapy, by Country/Region, 2024-2036 (USD Million)
Table 29. Acute Myeloid Leukemia Market for Cytarabine-Based Regimens, by Country/Region, 2024-2036 (USD Million)
Table 30. Acute Myeloid Leukemia Market for Anthracyclines, by Country/Region, 2024-2036 (USD Million)
Table 31. Acute Myeloid Leukemia Market for Liposomal Chemotherapy Formulations, by Country/Region, 2024-2036 (USD Million)
Table 32. Acute Myeloid Leukemia Market for Hypomethylating-Free Low-Intensity Regimens, by Country/Region, 2024-2036 (USD Million)
Table 33. Global Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 34. Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Country/Region, 2024-2036 (USD Million)
Table 35. Acute Myeloid Leukemia Market for CD33-Directed Antibody-Drug Conjugates, by Country/Region, 2024-2036 (USD Million)
Table 36. Acute Myeloid Leukemia Market for CD123-Directed Agents, by Country/Region, 2024-2036 (USD Million)
Table 37. Acute Myeloid Leukemia Market for Bispecific T-Cell Engagers, by Country/Region, 2024-2036 (USD Million)
Table 38. Acute Myeloid Leukemia Market for Immune Checkpoint and Macrophage Checkpoint Agents, by Country/Region, 2024-2036 (USD Million)
Table 39. Global Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 40. Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Country/Region, 2024-2036 (USD Million)
Table 41. Acute Myeloid Leukemia Market for Autologous CAR-T Therapy, by Country/Region, 2024-2036 (USD Million)
Table 42. Acute Myeloid Leukemia Market for Allogeneic CAR-T and CAR-NK Therapy, by Country/Region, 2024-2036 (USD Million)
Table 43. Acute Myeloid Leukemia Market for Donor Lymphocyte and Adoptive Cell Approaches, by Country/Region, 2024-2036 (USD Million)
Table 44. Acute Myeloid Leukemia Market for Supportive Care & Adjunct Therapy, by Country/Region, 2024-2036 (USD Million)
Table 45. Global Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 46. Acute Myeloid Leukemia Market for Mutation-Agnostic & Broad-Spectrum Regimens, by Country/Region, 2024-2036 (USD Million)
Table 47. Acute Myeloid Leukemia Market for NPM1-Mutated Disease, by Country/Region, 2024-2036 (USD Million)
Table 48. Global Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 49. Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Country/Region, 2024-2036 (USD Million)
Table 50. Acute Myeloid Leukemia Market for FLT3-ITD, by Country/Region, 2024-2036 (USD Million)
Table 51. Acute Myeloid Leukemia Market for FLT3-TKD, by Country/Region, 2024-2036 (USD Million)
Table 52. Global Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 53. Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Country/Region, 2024-2036 (USD Million)
Table 54. Acute Myeloid Leukemia Market for IDH1-Mutated, by Country/Region, 2024-2036 (USD Million)
Table 55. Acute Myeloid Leukemia Market for IDH2-Mutated, by Country/Region, 2024-2036 (USD Million)
Table 56. Acute Myeloid Leukemia Market for KMT2A-Rearranged Disease, by Country/Region, 2024-2036 (USD Million)
Table 57. Acute Myeloid Leukemia Market for TP53-Mutated & Adverse-Risk Disease, by Country/Region, 2024-2036 (USD Million)
Table 58. Acute Myeloid Leukemia Market for Other Molecular Subtypes, by Country/Region, 2024-2036 (USD Million)
Table 59. Global Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 60. Global Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 61. Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Country/Region, 2024-2036 (USD Million)
Table 62. Acute Myeloid Leukemia Market for Intensive Induction, by Country/Region, 2024-2036 (USD Million)
Table 63. Acute Myeloid Leukemia Market for Lower-Intensity Induction, by Country/Region, 2024-2036 (USD Million)
Table 64. Acute Myeloid Leukemia Market for Consolidation Therapy, by Country/Region, 2024-2036 (USD Million)
Table 65. Global Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 66. Acute Myeloid Leukemia Market for Maintenance Therapy, by Country/Region, 2024-2036 (USD Million)
Table 67. Acute Myeloid Leukemia Market for Post-Remission Maintenance, by Country/Region, 2024-2036 (USD Million)
Table 68. Acute Myeloid Leukemia Market for Post-Transplant Maintenance, by Country/Region, 2024-2036 (USD Million)
Table 69. Global Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 70. Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Country/Region, 2024-2036 (USD Million)
Table 71. Acute Myeloid Leukemia Market for First Relapse, by Country/Region, 2024-2036 (USD Million)
Table 72. Acute Myeloid Leukemia Market for Second and Later Relapse, by Country/Region, 2024-2036 (USD Million)
Table 73. Acute Myeloid Leukemia Market for Primary Refractory Disease, by Country/Region, 2024-2036 (USD Million)
Table 74. Global Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 75. Global Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 76. Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Country/Region, 2024-2036 (USD Million)
Table 77. Acute Myeloid Leukemia Market for Age-Based Ineligibility, by Country/Region, 2024-2036 (USD Million)
Table 78. Acute Myeloid Leukemia Market for Comorbidity and Performance Status-Based Ineligibility, by Country/Region, 2024-2036 (USD Million)
Table 79. Global Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 80. Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Country/Region, 2024-2036 (USD Million)
Table 81. Acute Myeloid Leukemia Market for Transplant-Eligible Patients, by Country/Region, 2024-2036 (USD Million)
Table 82. Acute Myeloid Leukemia Market for Transplant-Ineligible Patients, by Country/Region, 2024-2036 (USD Million)
Table 83. Global Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 84. Global Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 85. Acute Myeloid Leukemia Market for Oral, by Country/Region, 2024-2036 (USD Million)
Table 86. Acute Myeloid Leukemia Market for Oral Targeted Agents, by Country/Region, 2024-2036 (USD Million)
Table 87. Acute Myeloid Leukemia Market for Oral Hypomethylating Agents, by Country/Region, 2024-2036 (USD Million)
Table 88. Global Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 89. Acute Myeloid Leukemia Market for Intravenous, by Country/Region, 2024-2036 (USD Million)
Table 90. Acute Myeloid Leukemia Market for Cytotoxic Infusion, by Country/Region, 2024-2036 (USD Million)
Table 91. Acute Myeloid Leukemia Market for Antibody and Conjugate Infusion, by Country/Region, 2024-2036 (USD Million)
Table 92. Acute Myeloid Leukemia Market for Subcutaneous, by Country/Region, 2024-2036 (USD Million)
Table 93. Global Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 94. Acute Myeloid Leukemia Market for Outpatient & Ambulatory Care, by Country/Region, 2024-2036 (USD Million)
Table 95. Acute Myeloid Leukemia Market for Inpatient Hospital Care, by Country/Region, 2024-2036 (USD Million)
Table 96. Acute Myeloid Leukemia Market for Home-Based Care, by Country/Region, 2024-2036 (USD Million)
Table 97. Global Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 98. Acute Myeloid Leukemia Market for Hospitals & Academic Cancer Centers, by Country/Region, 2024-2036 (USD Million)
Table 99. Acute Myeloid Leukemia Market for Specialty Haematology & Community Oncology Practices, by Country/Region, 2024-2036 (USD Million)
Table 100. Acute Myeloid Leukemia Market for Transplantation Centers, by Country/Region, 2024-2036 (USD Million)
Table 101. Acute Myeloid Leukemia Market for Specialty Pharmacies, by Country/Region, 2024-2036 (USD Million)
Table 102. Acute Myeloid Leukemia Market for Other End Users, by Country/Region, 2024-2036 (USD Million)
Table 103. Global Acute Myeloid Leukemia Market, by Region, 2024-2036 (USD Million)
Table 104. Global Acute Myeloid Leukemia Market, by Country/Region, 2024-2036 (USD Million)
Table 105. North America: Acute Myeloid Leukemia Market, by Country, 2024-2036 (USD Million)
Table 106. North America: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 107. North America: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 108. North America: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 109. North America: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 110. North America: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 111. North America: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 112. North America: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 113. North America: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 114. North America: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 115. North America: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 116. North America: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 117. North America: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 118. North America: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 119. North America: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 120. North America: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 121. North America: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 122. North America: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 123. North America: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 124. North America: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 125. North America: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 126. North America: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 127. U.S.: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 128. U.S.: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 129. U.S.: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 130. U.S.: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 131. U.S.: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 132. U.S.: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 133. U.S.: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 134. U.S.: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 135. U.S.: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 136. U.S.: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 137. U.S.: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 138. U.S.: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 139. U.S.: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 140. U.S.: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 141. U.S.: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 142. U.S.: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 143. U.S.: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 144. U.S.: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 145. U.S.: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 146. U.S.: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 147. U.S.: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 148. Canada: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 149. Canada: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 150. Canada: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 151. Canada: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 152. Canada: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 153. Canada: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 154. Canada: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 155. Canada: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 156. Canada: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 157. Canada: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 158. Canada: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 159. Canada: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 160. Canada: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 161. Canada: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 162. Canada: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 163. Canada: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 164. Canada: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 165. Canada: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 166. Canada: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 167. Canada: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 168. Canada: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 169. Europe: Acute Myeloid Leukemia Market, by Country, 2024-2036 (USD Million)
Table 170. Europe: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 171. Europe: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 172. Europe: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 173. Europe: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 174. Europe: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 175. Europe: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 176. Europe: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 177. Europe: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 178. Europe: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 179. Europe: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 180. Europe: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 181. Europe: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 182. Europe: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 183. Europe: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 184. Europe: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 185. Europe: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 186. Europe: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 187. Europe: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 188. Europe: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 189. Europe: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 190. Europe: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 191. Germany: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 192. Germany: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 193. Germany: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 194. Germany: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 195. Germany: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 196. Germany: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 197. Germany: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 198. Germany: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 199. Germany: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 200. Germany: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 201. Germany: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 202. Germany: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 203. Germany: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 204. Germany: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 205. Germany: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 206. Germany: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 207. Germany: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 208. Germany: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 209. Germany: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 210. Germany: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 211. Germany: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 212. U.K.: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 213. U.K.: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 214. U.K.: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 215. U.K.: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 216. U.K.: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 217. U.K.: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 218. U.K.: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 219. U.K.: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 220. U.K.: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 221. U.K.: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 222. U.K.: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 223. U.K.: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 224. U.K.: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 225. U.K.: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 226. U.K.: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 227. U.K.: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 228. U.K.: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 229. U.K.: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 230. U.K.: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 231. U.K.: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 232. U.K.: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 233. France: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 234. France: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 235. France: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 236. France: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 237. France: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 238. France: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 239. France: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 240. France: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 241. France: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 242. France: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 243. France: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 244. France: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 245. France: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 246. France: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 247. France: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 248. France: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 249. France: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 250. France: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 251. France: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 252. France: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 253. France: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 254. Italy: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 255. Italy: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 256. Italy: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 257. Italy: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 258. Italy: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 259. Italy: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 260. Italy: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 261. Italy: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 262. Italy: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 263. Italy: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 264. Italy: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 265. Italy: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 266. Italy: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 267. Italy: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 268. Italy: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 269. Italy: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 270. Italy: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 271. Italy: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 272. Italy: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 273. Italy: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 274. Italy: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 275. Spain: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 276. Spain: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 277. Spain: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 278. Spain: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 279. Spain: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 280. Spain: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 281. Spain: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 282. Spain: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 283. Spain: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 284. Spain: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 285. Spain: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 286. Spain: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 287. Spain: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 288. Spain: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 289. Spain: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 290. Spain: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 291. Spain: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 292. Spain: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 293. Spain: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 294. Spain: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 295. Spain: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 296. Netherlands: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 297. Netherlands: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 298. Netherlands: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 299. Netherlands: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 300. Netherlands: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 301. Netherlands: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 302. Netherlands: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 303. Netherlands: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 304. Netherlands: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 305. Netherlands: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 306. Netherlands: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 307. Netherlands: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 308. Netherlands: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 309. Netherlands: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 310. Netherlands: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 311. Netherlands: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 312. Netherlands: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 313. Netherlands: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 314. Netherlands: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 315. Netherlands: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 316. Netherlands: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 317. Nordic Countries: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 318. Nordic Countries: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 319. Nordic Countries: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 320. Nordic Countries: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 321. Nordic Countries: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 322. Nordic Countries: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 323. Nordic Countries: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 324. Nordic Countries: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 325. Nordic Countries: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 326. Nordic Countries: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 327. Nordic Countries: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 328. Nordic Countries: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 329. Nordic Countries: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 330. Nordic Countries: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 331. Nordic Countries: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 332. Nordic Countries: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 333. Nordic Countries: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 334. Nordic Countries: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 335. Nordic Countries: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 336. Nordic Countries: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 337. Nordic Countries: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 338. Rest of Europe: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 339. Rest of Europe: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 340. Rest of Europe: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 341. Rest of Europe: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 342. Rest of Europe: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 343. Rest of Europe: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 344. Rest of Europe: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 345. Rest of Europe: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 346. Rest of Europe: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 347. Rest of Europe: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 348. Rest of Europe: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 349. Rest of Europe: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 350. Rest of Europe: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 351. Rest of Europe: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 352. Rest of Europe: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 353. Rest of Europe: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 354. Rest of Europe: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 355. Rest of Europe: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 356. Rest of Europe: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 357. Rest of Europe: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 358. Rest of Europe: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 359. Asia-Pacific: Acute Myeloid Leukemia Market, by Country, 2024-2036 (USD Million)
Table 360. Asia-Pacific: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 361. Asia-Pacific: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 362. Asia-Pacific: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 363. Asia-Pacific: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 364. Asia-Pacific: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 365. Asia-Pacific: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 366. Asia-Pacific: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 367. Asia-Pacific: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 368. Asia-Pacific: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 369. Asia-Pacific: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 370. Asia-Pacific: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 371. Asia-Pacific: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 372. Asia-Pacific: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 373. Asia-Pacific: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 374. Asia-Pacific: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 375. Asia-Pacific: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 376. Asia-Pacific: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 377. Asia-Pacific: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 378. Asia-Pacific: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 379. Asia-Pacific: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 380. Asia-Pacific: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 381. China: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 382. China: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 383. China: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 384. China: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 385. China: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 386. China: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 387. China: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 388. China: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 389. China: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 390. China: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 391. China: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 392. China: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 393. China: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 394. China: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 395. China: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 396. China: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 397. China: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 398. China: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 399. China: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 400. China: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 401. China: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 402. Japan: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 403. Japan: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 404. Japan: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 405. Japan: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 406. Japan: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 407. Japan: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 408. Japan: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 409. Japan: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 410. Japan: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 411. Japan: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 412. Japan: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 413. Japan: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 414. Japan: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 415. Japan: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 416. Japan: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 417. Japan: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 418. Japan: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 419. Japan: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 420. Japan: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 421. Japan: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 422. Japan: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 423. India: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 424. India: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 425. India: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 426. India: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 427. India: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 428. India: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 429. India: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 430. India: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 431. India: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 432. India: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 433. India: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 434. India: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 435. India: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 436. India: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 437. India: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 438. India: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 439. India: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 440. India: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 441. India: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 442. India: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 443. India: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 444. South Korea: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 445. South Korea: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 446. South Korea: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 447. South Korea: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 448. South Korea: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 449. South Korea: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 450. South Korea: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 451. South Korea: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 452. South Korea: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 453. South Korea: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 454. South Korea: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 455. South Korea: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 456. South Korea: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 457. South Korea: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 458. South Korea: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 459. South Korea: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 460. South Korea: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 461. South Korea: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 462. South Korea: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 463. South Korea: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 464. South Korea: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 465. Australia & New Zealand: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 466. Australia & New Zealand: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 467. Australia & New Zealand: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 468. Australia & New Zealand: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 469. Australia & New Zealand: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 470. Australia & New Zealand: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 471. Australia & New Zealand: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 472. Australia & New Zealand: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 473. Australia & New Zealand: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 474. Australia & New Zealand: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 475. Australia & New Zealand: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 476. Australia & New Zealand: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 477. Australia & New Zealand: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 478. Australia & New Zealand: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 479. Australia & New Zealand: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 480. Australia & New Zealand: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 481. Australia & New Zealand: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 482. Australia & New Zealand: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 483. Australia & New Zealand: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 484. Australia & New Zealand: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 485. Australia & New Zealand: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 486. Southeast Asia: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 487. Southeast Asia: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 488. Southeast Asia: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 489. Southeast Asia: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 490. Southeast Asia: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 491. Southeast Asia: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 492. Southeast Asia: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 493. Southeast Asia: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 494. Southeast Asia: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 495. Southeast Asia: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 496. Southeast Asia: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 497. Southeast Asia: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 498. Southeast Asia: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 499. Southeast Asia: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 500. Southeast Asia: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 501. Southeast Asia: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 502. Southeast Asia: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 503. Southeast Asia: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 504. Southeast Asia: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 505. Southeast Asia: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 506. Southeast Asia: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 507. Rest of Asia-Pacific: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 508. Rest of Asia-Pacific: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 509. Rest of Asia-Pacific: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 510. Rest of Asia-Pacific: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 511. Rest of Asia-Pacific: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 512. Rest of Asia-Pacific: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 513. Rest of Asia-Pacific: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 514. Rest of Asia-Pacific: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 515. Rest of Asia-Pacific: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 516. Rest of Asia-Pacific: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 517. Rest of Asia-Pacific: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 518. Rest of Asia-Pacific: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 519. Rest of Asia-Pacific: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 520. Rest of Asia-Pacific: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 521. Rest of Asia-Pacific: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 522. Rest of Asia-Pacific: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 523. Rest of Asia-Pacific: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 524. Rest of Asia-Pacific: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 525. Rest of Asia-Pacific: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 526. Rest of Asia-Pacific: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 527. Rest of Asia-Pacific: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 528. Latin America: Acute Myeloid Leukemia Market, by Country, 2024-2036 (USD Million)
Table 529. Latin America: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 530. Latin America: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 531. Latin America: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 532. Latin America: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 533. Latin America: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 534. Latin America: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 535. Latin America: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 536. Latin America: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 537. Latin America: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 538. Latin America: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 539. Latin America: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 540. Latin America: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 541. Latin America: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 542. Latin America: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 543. Latin America: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 544. Latin America: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 545. Latin America: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 546. Latin America: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 547. Latin America: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 548. Latin America: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 549. Latin America: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 550. Brazil: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 551. Brazil: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 552. Brazil: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 553. Brazil: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 554. Brazil: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 555. Brazil: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 556. Brazil: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 557. Brazil: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 558. Brazil: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 559. Brazil: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 560. Brazil: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 561. Brazil: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 562. Brazil: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 563. Brazil: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 564. Brazil: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 565. Brazil: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 566. Brazil: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 567. Brazil: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 568. Brazil: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 569. Brazil: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 570. Brazil: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 571. Mexico: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 572. Mexico: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 573. Mexico: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 574. Mexico: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 575. Mexico: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 576. Mexico: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 577. Mexico: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 578. Mexico: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 579. Mexico: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 580. Mexico: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 581. Mexico: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 582. Mexico: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 583. Mexico: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 584. Mexico: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 585. Mexico: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 586. Mexico: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 587. Mexico: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 588. Mexico: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 589. Mexico: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 590. Mexico: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 591. Mexico: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 592. Argentina: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 593. Argentina: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 594. Argentina: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 595. Argentina: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 596. Argentina: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 597. Argentina: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 598. Argentina: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 599. Argentina: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 600. Argentina: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 601. Argentina: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 602. Argentina: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 603. Argentina: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 604. Argentina: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 605. Argentina: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 606. Argentina: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 607. Argentina: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 608. Argentina: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 609. Argentina: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 610. Argentina: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 611. Argentina: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 612. Argentina: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 613. Colombia: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 614. Colombia: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 615. Colombia: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 616. Colombia: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 617. Colombia: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 618. Colombia: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 619. Colombia: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 620. Colombia: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 621. Colombia: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 622. Colombia: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 623. Colombia: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 624. Colombia: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 625. Colombia: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 626. Colombia: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 627. Colombia: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 628. Colombia: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 629. Colombia: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 630. Colombia: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 631. Colombia: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 632. Colombia: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 633. Colombia: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 634. Rest of Latin America: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 635. Rest of Latin America: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 636. Rest of Latin America: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 637. Rest of Latin America: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 638. Rest of Latin America: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 639. Rest of Latin America: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 640. Rest of Latin America: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 641. Rest of Latin America: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 642. Rest of Latin America: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 643. Rest of Latin America: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 644. Rest of Latin America: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 645. Rest of Latin America: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 646. Rest of Latin America: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 647. Rest of Latin America: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 648. Rest of Latin America: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 649. Rest of Latin America: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 650. Rest of Latin America: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 651. Rest of Latin America: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 652. Rest of Latin America: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 653. Rest of Latin America: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 654. Rest of Latin America: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 655. Middle East & Africa: Acute Myeloid Leukemia Market, by Country, 2024-2036 (USD Million)
Table 656. Middle East & Africa: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 657. Middle East & Africa: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 658. Middle East & Africa: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 659. Middle East & Africa: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 660. Middle East & Africa: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 661. Middle East & Africa: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 662. Middle East & Africa: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 663. Middle East & Africa: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 664. Middle East & Africa: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 665. Middle East & Africa: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 666. Middle East & Africa: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 667. Middle East & Africa: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 668. Middle East & Africa: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 669. Middle East & Africa: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 670. Middle East & Africa: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 671. Middle East & Africa: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 672. Middle East & Africa: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 673. Middle East & Africa: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 674. Middle East & Africa: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 675. Middle East & Africa: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 676. Middle East & Africa: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 677. Saudi Arabia: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 678. Saudi Arabia: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 679. Saudi Arabia: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 680. Saudi Arabia: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 681. Saudi Arabia: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 682. Saudi Arabia: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 683. Saudi Arabia: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 684. Saudi Arabia: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 685. Saudi Arabia: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 686. Saudi Arabia: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 687. Saudi Arabia: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 688. Saudi Arabia: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 689. Saudi Arabia: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 690. Saudi Arabia: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 691. Saudi Arabia: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 692. Saudi Arabia: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 693. Saudi Arabia: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 694. Saudi Arabia: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 695. Saudi Arabia: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 696. Saudi Arabia: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 697. Saudi Arabia: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 698. UAE: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 699. UAE: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 700. UAE: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 701. UAE: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 702. UAE: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 703. UAE: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 704. UAE: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 705. UAE: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 706. UAE: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 707. UAE: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 708. UAE: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 709. UAE: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 710. UAE: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 711. UAE: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 712. UAE: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 713. UAE: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 714. UAE: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 715. UAE: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 716. UAE: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 717. UAE: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 718. UAE: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 719. Israel: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 720. Israel: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 721. Israel: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 722. Israel: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 723. Israel: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 724. Israel: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 725. Israel: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 726. Israel: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 727. Israel: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 728. Israel: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 729. Israel: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 730. Israel: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 731. Israel: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 732. Israel: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 733. Israel: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 734. Israel: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 735. Israel: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 736. Israel: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 737. Israel: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 738. Israel: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 739. Israel: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 740. Turkey: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 741. Turkey: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 742. Turkey: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 743. Turkey: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 744. Turkey: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 745. Turkey: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 746. Turkey: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 747. Turkey: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 748. Turkey: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 749. Turkey: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 750. Turkey: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 751. Turkey: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 752. Turkey: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 753. Turkey: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 754. Turkey: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 755. Turkey: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 756. Turkey: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 757. Turkey: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 758. Turkey: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 759. Turkey: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 760. Turkey: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 761. South Africa: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 762. South Africa: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 763. South Africa: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 764. South Africa: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 765. South Africa: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 766. South Africa: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 767. South Africa: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 768. South Africa: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 769. South Africa: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 770. South Africa: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 771. South Africa: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 772. South Africa: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 773. South Africa: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 774. South Africa: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 775. South Africa: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 776. South Africa: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 777. South Africa: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 778. South Africa: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 779. South Africa: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 780. South Africa: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 781. South Africa: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 782. Egypt: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 783. Egypt: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 784. Egypt: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 785. Egypt: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 786. Egypt: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 787. Egypt: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 788. Egypt: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 789. Egypt: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 790. Egypt: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 791. Egypt: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 792. Egypt: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 793. Egypt: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 794. Egypt: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 795. Egypt: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 796. Egypt: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 797. Egypt: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 798. Egypt: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 799. Egypt: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 800. Egypt: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 801. Egypt: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 802. Egypt: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 803. Rest of Middle East & Africa: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 804. Rest of Middle East & Africa: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 805. Rest of Middle East & Africa: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 806. Rest of Middle East & Africa: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 807. Rest of Middle East & Africa: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 808. Rest of Middle East & Africa: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 809. Rest of Middle East & Africa: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 810. Rest of Middle East & Africa: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 811. Rest of Middle East & Africa: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 812. Rest of Middle East & Africa: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 813. Rest of Middle East & Africa: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 814. Rest of Middle East & Africa: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 815. Rest of Middle East & Africa: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 816. Rest of Middle East & Africa: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 817. Rest of Middle East & Africa: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 818. Rest of Middle East & Africa: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 819. Rest of Middle East & Africa: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 820. Rest of Middle East & Africa: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 821. Rest of Middle East & Africa: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 822. Rest of Middle East & Africa: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 823. Rest of Middle East & Africa: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 824. Acute Myeloid Leukemia Market: Key Growth Strategies Adopted by Leading Players (2024-2026)
Table 825. Acute Myeloid Leukemia Market: Strategic Developments, by Company (2024-2026)
Table 826. Acute Myeloid Leukemia Market: Competitive Benchmarking
Table 827. Acute Myeloid Leukemia Market: Market Share/Ranking Analysis, by Key Player (2025)
Table 828. AbbVie Inc.: Product Portfolio
Table 829. AbbVie Inc.: Strategic Developments
Table 830. F. Hoffmann-La Roche Ltd: Product Portfolio
Table 831. F. Hoffmann-La Roche Ltd: Strategic Developments
Table 832. Astellas Pharma Inc.: Product Portfolio
Table 833. Astellas Pharma Inc.: Strategic Developments
Table 834. Novartis AG: Product Portfolio
Table 835. Novartis AG: Strategic Developments
Table 836. Daiichi Sankyo Company, Limited: Product Portfolio
Table 837. Daiichi Sankyo Company, Limited: Strategic Developments
Table 838. Servier Laboratories: Product Portfolio
Table 839. Servier Laboratories: Strategic Developments
Table 840. Bristol-Myers Squibb Company: Product Portfolio
Table 841. Bristol-Myers Squibb Company: Strategic Developments
Table 842. Pfizer Inc.: Product Portfolio
Table 843. Pfizer Inc.: Strategic Developments
Table 844. Jazz Pharmaceuticals plc: Product Portfolio
Table 845. Jazz Pharmaceuticals plc: Strategic Developments
Table 846. Syndax Pharmaceuticals, Inc.: Product Portfolio
Table 847. Syndax Pharmaceuticals, Inc.: Strategic Developments
Table 848. Kura Oncology, Inc.: Product Portfolio
Table 849. Kura Oncology, Inc.: Strategic Developments
Table 850. Kyowa Kirin Co., Ltd.: Product Portfolio
Table 851. Kyowa Kirin Co., Ltd.: Strategic Developments
Table 852. Otsuka Pharmaceutical Co., Ltd.: Product Portfolio
Table 853. Otsuka Pharmaceutical Co., Ltd.: Strategic Developments
Table 854. Taiho Pharmaceutical Co., Ltd.: Product Portfolio
Table 855. Taiho Pharmaceutical Co., Ltd.: Strategic Developments
Table 856. Rigel Pharmaceuticals, Inc.: Product Portfolio
Table 857. Rigel Pharmaceuticals, Inc.: Strategic Developments
Table 858. Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 859. Teva Pharmaceutical Industries Ltd.: Strategic Developments
Table 860. Sandoz Group AG: Product Portfolio
Table 861. Sandoz Group AG: Strategic Developments
Table 862. Dr. Reddy's Laboratories Ltd.: Product Portfolio
Table 863. Dr. Reddy's Laboratories Ltd.: Strategic Developments
Table 864. Hikma Pharmaceuticals PLC: Product Portfolio
Table 865. Hikma Pharmaceuticals PLC: Strategic Developments
Table 866. Johnson & Johnson: Product Portfolio
Table 867. Johnson & Johnson: Strategic Developments
Table 868. Sumitomo Pharma Co., Ltd.: Product Portfolio
Table 869. Sumitomo Pharma Co., Ltd.: Strategic Developments
Table 870. Aptose Biosciences Inc.: Product Portfolio
Table 871. Aptose Biosciences Inc.: Strategic Developments
Table 872. Immune-Onc Therapeutics, Inc.: Product Portfolio
Table 873. Immune-Onc Therapeutics, Inc.: Strategic Developments
Table 874. Available Customization Options
Table 875. Available Related Reports
Table 2. Global Acute Myeloid Leukemia Market Restraints: Impact Analysis (2026-2036)
Table 3. Global Acute Myeloid Leukemia Market Opportunities: Impact Analysis (2026-2036)
Table 4. Global Acute Myeloid Leukemia Market Challenges: Impact Analysis (2026-2036)
Table 5. Global Leukemia Incidence and Mortality, by Region (IARC, 2022)
Table 6. Acute Myeloid Leukemia Incidence, by Age Group (SEER)
Table 7. Prevalence of Key Molecular Alterations in AML (NPM1, FLT3, IDH1/2, KMT2A, TP53)
Table 8. Approved AML Therapies, by Mechanism, Indication and Companion Diagnostic
Table 9. Selected Late-Stage AML Pipeline Candidates, by Mechanism and Line of Therapy
Table 10. Annual Cost of Therapy, by Regimen Class
Table 11. Exclusivity Timelines for Branded Targeted AML Agents
Table 12. Key Licensing, Partnership and Co-Development Agreements in AML
Table 13. Porter's Five Forces Analysis: Acute Myeloid Leukemia Market
Table 14. Global Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 15. Global Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 16. Acute Myeloid Leukemia Market for Targeted Therapy, by Country/Region, 2024-2036 (USD Million)
Table 17. Acute Myeloid Leukemia Market for Menin Inhibitors, by Country/Region, 2024-2036 (USD Million)
Table 18. Acute Myeloid Leukemia Market for BCL-2 Inhibitors, by Country/Region, 2024-2036 (USD Million)
Table 19. Acute Myeloid Leukemia Market for FLT3 Inhibitors, by Country/Region, 2024-2036 (USD Million)
Table 20. Acute Myeloid Leukemia Market for IDH Inhibitors, by Country/Region, 2024-2036 (USD Million)
Table 21. Acute Myeloid Leukemia Market for Hedgehog Pathway Inhibitors, by Country/Region, 2024-2036 (USD Million)
Table 22. Acute Myeloid Leukemia Market for Other Targeted Agents, by Country/Region, 2024-2036 (USD Million)
Table 23. Global Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 24. Acute Myeloid Leukemia Market for Hypomethylating Agents, by Country/Region, 2024-2036 (USD Million)
Table 25. Acute Myeloid Leukemia Market for Injectable Hypomethylating Agents, by Country/Region, 2024-2036 (USD Million)
Table 26. Acute Myeloid Leukemia Market for Oral Hypomethylating Agents, by Country/Region, 2024-2036 (USD Million)
Table 27. Global Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 28. Acute Myeloid Leukemia Market for Chemotherapy, by Country/Region, 2024-2036 (USD Million)
Table 29. Acute Myeloid Leukemia Market for Cytarabine-Based Regimens, by Country/Region, 2024-2036 (USD Million)
Table 30. Acute Myeloid Leukemia Market for Anthracyclines, by Country/Region, 2024-2036 (USD Million)
Table 31. Acute Myeloid Leukemia Market for Liposomal Chemotherapy Formulations, by Country/Region, 2024-2036 (USD Million)
Table 32. Acute Myeloid Leukemia Market for Hypomethylating-Free Low-Intensity Regimens, by Country/Region, 2024-2036 (USD Million)
Table 33. Global Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 34. Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Country/Region, 2024-2036 (USD Million)
Table 35. Acute Myeloid Leukemia Market for CD33-Directed Antibody-Drug Conjugates, by Country/Region, 2024-2036 (USD Million)
Table 36. Acute Myeloid Leukemia Market for CD123-Directed Agents, by Country/Region, 2024-2036 (USD Million)
Table 37. Acute Myeloid Leukemia Market for Bispecific T-Cell Engagers, by Country/Region, 2024-2036 (USD Million)
Table 38. Acute Myeloid Leukemia Market for Immune Checkpoint and Macrophage Checkpoint Agents, by Country/Region, 2024-2036 (USD Million)
Table 39. Global Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 40. Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Country/Region, 2024-2036 (USD Million)
Table 41. Acute Myeloid Leukemia Market for Autologous CAR-T Therapy, by Country/Region, 2024-2036 (USD Million)
Table 42. Acute Myeloid Leukemia Market for Allogeneic CAR-T and CAR-NK Therapy, by Country/Region, 2024-2036 (USD Million)
Table 43. Acute Myeloid Leukemia Market for Donor Lymphocyte and Adoptive Cell Approaches, by Country/Region, 2024-2036 (USD Million)
Table 44. Acute Myeloid Leukemia Market for Supportive Care & Adjunct Therapy, by Country/Region, 2024-2036 (USD Million)
Table 45. Global Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 46. Acute Myeloid Leukemia Market for Mutation-Agnostic & Broad-Spectrum Regimens, by Country/Region, 2024-2036 (USD Million)
Table 47. Acute Myeloid Leukemia Market for NPM1-Mutated Disease, by Country/Region, 2024-2036 (USD Million)
Table 48. Global Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 49. Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Country/Region, 2024-2036 (USD Million)
Table 50. Acute Myeloid Leukemia Market for FLT3-ITD, by Country/Region, 2024-2036 (USD Million)
Table 51. Acute Myeloid Leukemia Market for FLT3-TKD, by Country/Region, 2024-2036 (USD Million)
Table 52. Global Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 53. Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Country/Region, 2024-2036 (USD Million)
Table 54. Acute Myeloid Leukemia Market for IDH1-Mutated, by Country/Region, 2024-2036 (USD Million)
Table 55. Acute Myeloid Leukemia Market for IDH2-Mutated, by Country/Region, 2024-2036 (USD Million)
Table 56. Acute Myeloid Leukemia Market for KMT2A-Rearranged Disease, by Country/Region, 2024-2036 (USD Million)
Table 57. Acute Myeloid Leukemia Market for TP53-Mutated & Adverse-Risk Disease, by Country/Region, 2024-2036 (USD Million)
Table 58. Acute Myeloid Leukemia Market for Other Molecular Subtypes, by Country/Region, 2024-2036 (USD Million)
Table 59. Global Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 60. Global Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 61. Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Country/Region, 2024-2036 (USD Million)
Table 62. Acute Myeloid Leukemia Market for Intensive Induction, by Country/Region, 2024-2036 (USD Million)
Table 63. Acute Myeloid Leukemia Market for Lower-Intensity Induction, by Country/Region, 2024-2036 (USD Million)
Table 64. Acute Myeloid Leukemia Market for Consolidation Therapy, by Country/Region, 2024-2036 (USD Million)
Table 65. Global Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 66. Acute Myeloid Leukemia Market for Maintenance Therapy, by Country/Region, 2024-2036 (USD Million)
Table 67. Acute Myeloid Leukemia Market for Post-Remission Maintenance, by Country/Region, 2024-2036 (USD Million)
Table 68. Acute Myeloid Leukemia Market for Post-Transplant Maintenance, by Country/Region, 2024-2036 (USD Million)
Table 69. Global Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 70. Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Country/Region, 2024-2036 (USD Million)
Table 71. Acute Myeloid Leukemia Market for First Relapse, by Country/Region, 2024-2036 (USD Million)
Table 72. Acute Myeloid Leukemia Market for Second and Later Relapse, by Country/Region, 2024-2036 (USD Million)
Table 73. Acute Myeloid Leukemia Market for Primary Refractory Disease, by Country/Region, 2024-2036 (USD Million)
Table 74. Global Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 75. Global Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 76. Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Country/Region, 2024-2036 (USD Million)
Table 77. Acute Myeloid Leukemia Market for Age-Based Ineligibility, by Country/Region, 2024-2036 (USD Million)
Table 78. Acute Myeloid Leukemia Market for Comorbidity and Performance Status-Based Ineligibility, by Country/Region, 2024-2036 (USD Million)
Table 79. Global Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 80. Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Country/Region, 2024-2036 (USD Million)
Table 81. Acute Myeloid Leukemia Market for Transplant-Eligible Patients, by Country/Region, 2024-2036 (USD Million)
Table 82. Acute Myeloid Leukemia Market for Transplant-Ineligible Patients, by Country/Region, 2024-2036 (USD Million)
Table 83. Global Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 84. Global Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 85. Acute Myeloid Leukemia Market for Oral, by Country/Region, 2024-2036 (USD Million)
Table 86. Acute Myeloid Leukemia Market for Oral Targeted Agents, by Country/Region, 2024-2036 (USD Million)
Table 87. Acute Myeloid Leukemia Market for Oral Hypomethylating Agents, by Country/Region, 2024-2036 (USD Million)
Table 88. Global Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 89. Acute Myeloid Leukemia Market for Intravenous, by Country/Region, 2024-2036 (USD Million)
Table 90. Acute Myeloid Leukemia Market for Cytotoxic Infusion, by Country/Region, 2024-2036 (USD Million)
Table 91. Acute Myeloid Leukemia Market for Antibody and Conjugate Infusion, by Country/Region, 2024-2036 (USD Million)
Table 92. Acute Myeloid Leukemia Market for Subcutaneous, by Country/Region, 2024-2036 (USD Million)
Table 93. Global Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 94. Acute Myeloid Leukemia Market for Outpatient & Ambulatory Care, by Country/Region, 2024-2036 (USD Million)
Table 95. Acute Myeloid Leukemia Market for Inpatient Hospital Care, by Country/Region, 2024-2036 (USD Million)
Table 96. Acute Myeloid Leukemia Market for Home-Based Care, by Country/Region, 2024-2036 (USD Million)
Table 97. Global Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 98. Acute Myeloid Leukemia Market for Hospitals & Academic Cancer Centers, by Country/Region, 2024-2036 (USD Million)
Table 99. Acute Myeloid Leukemia Market for Specialty Haematology & Community Oncology Practices, by Country/Region, 2024-2036 (USD Million)
Table 100. Acute Myeloid Leukemia Market for Transplantation Centers, by Country/Region, 2024-2036 (USD Million)
Table 101. Acute Myeloid Leukemia Market for Specialty Pharmacies, by Country/Region, 2024-2036 (USD Million)
Table 102. Acute Myeloid Leukemia Market for Other End Users, by Country/Region, 2024-2036 (USD Million)
Table 103. Global Acute Myeloid Leukemia Market, by Region, 2024-2036 (USD Million)
Table 104. Global Acute Myeloid Leukemia Market, by Country/Region, 2024-2036 (USD Million)
Table 105. North America: Acute Myeloid Leukemia Market, by Country, 2024-2036 (USD Million)
Table 106. North America: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 107. North America: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 108. North America: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 109. North America: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 110. North America: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 111. North America: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 112. North America: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 113. North America: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 114. North America: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 115. North America: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 116. North America: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 117. North America: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 118. North America: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 119. North America: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 120. North America: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 121. North America: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 122. North America: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 123. North America: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 124. North America: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 125. North America: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 126. North America: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 127. U.S.: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 128. U.S.: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 129. U.S.: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 130. U.S.: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 131. U.S.: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 132. U.S.: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 133. U.S.: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 134. U.S.: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 135. U.S.: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 136. U.S.: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 137. U.S.: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 138. U.S.: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 139. U.S.: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 140. U.S.: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 141. U.S.: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 142. U.S.: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 143. U.S.: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 144. U.S.: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 145. U.S.: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 146. U.S.: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 147. U.S.: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 148. Canada: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 149. Canada: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 150. Canada: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 151. Canada: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 152. Canada: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 153. Canada: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 154. Canada: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 155. Canada: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 156. Canada: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 157. Canada: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 158. Canada: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 159. Canada: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 160. Canada: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 161. Canada: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 162. Canada: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 163. Canada: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 164. Canada: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 165. Canada: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 166. Canada: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 167. Canada: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 168. Canada: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 169. Europe: Acute Myeloid Leukemia Market, by Country, 2024-2036 (USD Million)
Table 170. Europe: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 171. Europe: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 172. Europe: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 173. Europe: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 174. Europe: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 175. Europe: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 176. Europe: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 177. Europe: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 178. Europe: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 179. Europe: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 180. Europe: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 181. Europe: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 182. Europe: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 183. Europe: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 184. Europe: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 185. Europe: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 186. Europe: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 187. Europe: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 188. Europe: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 189. Europe: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 190. Europe: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 191. Germany: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 192. Germany: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 193. Germany: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 194. Germany: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 195. Germany: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 196. Germany: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 197. Germany: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 198. Germany: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 199. Germany: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 200. Germany: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 201. Germany: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 202. Germany: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 203. Germany: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 204. Germany: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 205. Germany: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 206. Germany: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 207. Germany: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 208. Germany: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 209. Germany: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 210. Germany: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 211. Germany: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 212. U.K.: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 213. U.K.: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 214. U.K.: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 215. U.K.: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 216. U.K.: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 217. U.K.: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 218. U.K.: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 219. U.K.: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 220. U.K.: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 221. U.K.: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 222. U.K.: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 223. U.K.: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 224. U.K.: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 225. U.K.: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 226. U.K.: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 227. U.K.: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 228. U.K.: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 229. U.K.: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 230. U.K.: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 231. U.K.: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 232. U.K.: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 233. France: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 234. France: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 235. France: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 236. France: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 237. France: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 238. France: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 239. France: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 240. France: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 241. France: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 242. France: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 243. France: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 244. France: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 245. France: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 246. France: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 247. France: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 248. France: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 249. France: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 250. France: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 251. France: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 252. France: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 253. France: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 254. Italy: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 255. Italy: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 256. Italy: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 257. Italy: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 258. Italy: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 259. Italy: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 260. Italy: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 261. Italy: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 262. Italy: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 263. Italy: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 264. Italy: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 265. Italy: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 266. Italy: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 267. Italy: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 268. Italy: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 269. Italy: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 270. Italy: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 271. Italy: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 272. Italy: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 273. Italy: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 274. Italy: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 275. Spain: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 276. Spain: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 277. Spain: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 278. Spain: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 279. Spain: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 280. Spain: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 281. Spain: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 282. Spain: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 283. Spain: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 284. Spain: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 285. Spain: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 286. Spain: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 287. Spain: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 288. Spain: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 289. Spain: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 290. Spain: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 291. Spain: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 292. Spain: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 293. Spain: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 294. Spain: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 295. Spain: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 296. Netherlands: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 297. Netherlands: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 298. Netherlands: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 299. Netherlands: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 300. Netherlands: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 301. Netherlands: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 302. Netherlands: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 303. Netherlands: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 304. Netherlands: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 305. Netherlands: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 306. Netherlands: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 307. Netherlands: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 308. Netherlands: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 309. Netherlands: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 310. Netherlands: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 311. Netherlands: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 312. Netherlands: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 313. Netherlands: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 314. Netherlands: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 315. Netherlands: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 316. Netherlands: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 317. Nordic Countries: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 318. Nordic Countries: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 319. Nordic Countries: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 320. Nordic Countries: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 321. Nordic Countries: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 322. Nordic Countries: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 323. Nordic Countries: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 324. Nordic Countries: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 325. Nordic Countries: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 326. Nordic Countries: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 327. Nordic Countries: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 328. Nordic Countries: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 329. Nordic Countries: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 330. Nordic Countries: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 331. Nordic Countries: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 332. Nordic Countries: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 333. Nordic Countries: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 334. Nordic Countries: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 335. Nordic Countries: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 336. Nordic Countries: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 337. Nordic Countries: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 338. Rest of Europe: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 339. Rest of Europe: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 340. Rest of Europe: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 341. Rest of Europe: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 342. Rest of Europe: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 343. Rest of Europe: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 344. Rest of Europe: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 345. Rest of Europe: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 346. Rest of Europe: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 347. Rest of Europe: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 348. Rest of Europe: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 349. Rest of Europe: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 350. Rest of Europe: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 351. Rest of Europe: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 352. Rest of Europe: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 353. Rest of Europe: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 354. Rest of Europe: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 355. Rest of Europe: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 356. Rest of Europe: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 357. Rest of Europe: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 358. Rest of Europe: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 359. Asia-Pacific: Acute Myeloid Leukemia Market, by Country, 2024-2036 (USD Million)
Table 360. Asia-Pacific: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 361. Asia-Pacific: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 362. Asia-Pacific: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 363. Asia-Pacific: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 364. Asia-Pacific: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 365. Asia-Pacific: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 366. Asia-Pacific: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 367. Asia-Pacific: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 368. Asia-Pacific: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 369. Asia-Pacific: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 370. Asia-Pacific: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 371. Asia-Pacific: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 372. Asia-Pacific: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 373. Asia-Pacific: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 374. Asia-Pacific: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 375. Asia-Pacific: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 376. Asia-Pacific: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 377. Asia-Pacific: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 378. Asia-Pacific: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 379. Asia-Pacific: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 380. Asia-Pacific: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 381. China: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 382. China: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 383. China: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 384. China: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 385. China: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 386. China: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 387. China: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 388. China: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 389. China: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 390. China: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 391. China: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 392. China: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 393. China: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 394. China: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 395. China: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 396. China: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 397. China: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 398. China: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 399. China: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 400. China: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 401. China: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 402. Japan: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 403. Japan: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 404. Japan: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 405. Japan: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 406. Japan: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 407. Japan: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 408. Japan: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 409. Japan: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 410. Japan: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 411. Japan: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 412. Japan: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 413. Japan: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 414. Japan: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 415. Japan: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 416. Japan: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 417. Japan: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 418. Japan: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 419. Japan: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 420. Japan: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 421. Japan: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 422. Japan: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 423. India: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 424. India: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 425. India: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 426. India: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 427. India: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 428. India: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 429. India: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 430. India: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 431. India: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 432. India: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 433. India: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 434. India: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 435. India: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 436. India: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 437. India: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 438. India: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 439. India: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 440. India: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 441. India: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 442. India: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 443. India: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 444. South Korea: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 445. South Korea: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 446. South Korea: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 447. South Korea: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 448. South Korea: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 449. South Korea: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 450. South Korea: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 451. South Korea: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 452. South Korea: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 453. South Korea: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 454. South Korea: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 455. South Korea: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 456. South Korea: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 457. South Korea: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 458. South Korea: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 459. South Korea: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 460. South Korea: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 461. South Korea: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 462. South Korea: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 463. South Korea: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 464. South Korea: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 465. Australia & New Zealand: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 466. Australia & New Zealand: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 467. Australia & New Zealand: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 468. Australia & New Zealand: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 469. Australia & New Zealand: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 470. Australia & New Zealand: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 471. Australia & New Zealand: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 472. Australia & New Zealand: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 473. Australia & New Zealand: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 474. Australia & New Zealand: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 475. Australia & New Zealand: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 476. Australia & New Zealand: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 477. Australia & New Zealand: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 478. Australia & New Zealand: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 479. Australia & New Zealand: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 480. Australia & New Zealand: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 481. Australia & New Zealand: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 482. Australia & New Zealand: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 483. Australia & New Zealand: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 484. Australia & New Zealand: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 485. Australia & New Zealand: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 486. Southeast Asia: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 487. Southeast Asia: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 488. Southeast Asia: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 489. Southeast Asia: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 490. Southeast Asia: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 491. Southeast Asia: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 492. Southeast Asia: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 493. Southeast Asia: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 494. Southeast Asia: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 495. Southeast Asia: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 496. Southeast Asia: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 497. Southeast Asia: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 498. Southeast Asia: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 499. Southeast Asia: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 500. Southeast Asia: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 501. Southeast Asia: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 502. Southeast Asia: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 503. Southeast Asia: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 504. Southeast Asia: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 505. Southeast Asia: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 506. Southeast Asia: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 507. Rest of Asia-Pacific: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 508. Rest of Asia-Pacific: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 509. Rest of Asia-Pacific: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 510. Rest of Asia-Pacific: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 511. Rest of Asia-Pacific: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 512. Rest of Asia-Pacific: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 513. Rest of Asia-Pacific: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 514. Rest of Asia-Pacific: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 515. Rest of Asia-Pacific: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 516. Rest of Asia-Pacific: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 517. Rest of Asia-Pacific: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 518. Rest of Asia-Pacific: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 519. Rest of Asia-Pacific: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 520. Rest of Asia-Pacific: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 521. Rest of Asia-Pacific: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 522. Rest of Asia-Pacific: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 523. Rest of Asia-Pacific: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 524. Rest of Asia-Pacific: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 525. Rest of Asia-Pacific: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 526. Rest of Asia-Pacific: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 527. Rest of Asia-Pacific: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 528. Latin America: Acute Myeloid Leukemia Market, by Country, 2024-2036 (USD Million)
Table 529. Latin America: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 530. Latin America: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 531. Latin America: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 532. Latin America: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 533. Latin America: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 534. Latin America: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 535. Latin America: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 536. Latin America: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 537. Latin America: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 538. Latin America: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 539. Latin America: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 540. Latin America: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 541. Latin America: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 542. Latin America: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 543. Latin America: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 544. Latin America: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 545. Latin America: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 546. Latin America: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 547. Latin America: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 548. Latin America: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 549. Latin America: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 550. Brazil: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 551. Brazil: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 552. Brazil: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 553. Brazil: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 554. Brazil: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 555. Brazil: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 556. Brazil: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 557. Brazil: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 558. Brazil: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 559. Brazil: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 560. Brazil: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 561. Brazil: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 562. Brazil: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 563. Brazil: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 564. Brazil: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 565. Brazil: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 566. Brazil: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 567. Brazil: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 568. Brazil: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 569. Brazil: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 570. Brazil: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 571. Mexico: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 572. Mexico: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 573. Mexico: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 574. Mexico: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 575. Mexico: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 576. Mexico: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 577. Mexico: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 578. Mexico: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 579. Mexico: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 580. Mexico: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 581. Mexico: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 582. Mexico: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 583. Mexico: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 584. Mexico: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 585. Mexico: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 586. Mexico: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 587. Mexico: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 588. Mexico: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 589. Mexico: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 590. Mexico: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 591. Mexico: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 592. Argentina: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 593. Argentina: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 594. Argentina: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 595. Argentina: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 596. Argentina: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 597. Argentina: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 598. Argentina: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 599. Argentina: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 600. Argentina: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 601. Argentina: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 602. Argentina: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 603. Argentina: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 604. Argentina: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 605. Argentina: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 606. Argentina: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 607. Argentina: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 608. Argentina: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 609. Argentina: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 610. Argentina: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 611. Argentina: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 612. Argentina: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 613. Colombia: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 614. Colombia: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 615. Colombia: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 616. Colombia: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 617. Colombia: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 618. Colombia: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 619. Colombia: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 620. Colombia: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 621. Colombia: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 622. Colombia: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 623. Colombia: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 624. Colombia: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 625. Colombia: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 626. Colombia: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 627. Colombia: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 628. Colombia: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 629. Colombia: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 630. Colombia: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 631. Colombia: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 632. Colombia: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 633. Colombia: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 634. Rest of Latin America: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 635. Rest of Latin America: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 636. Rest of Latin America: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 637. Rest of Latin America: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 638. Rest of Latin America: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 639. Rest of Latin America: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 640. Rest of Latin America: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 641. Rest of Latin America: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 642. Rest of Latin America: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 643. Rest of Latin America: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 644. Rest of Latin America: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 645. Rest of Latin America: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 646. Rest of Latin America: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 647. Rest of Latin America: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 648. Rest of Latin America: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 649. Rest of Latin America: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 650. Rest of Latin America: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 651. Rest of Latin America: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 652. Rest of Latin America: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 653. Rest of Latin America: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 654. Rest of Latin America: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 655. Middle East & Africa: Acute Myeloid Leukemia Market, by Country, 2024-2036 (USD Million)
Table 656. Middle East & Africa: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 657. Middle East & Africa: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 658. Middle East & Africa: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 659. Middle East & Africa: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 660. Middle East & Africa: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 661. Middle East & Africa: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 662. Middle East & Africa: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 663. Middle East & Africa: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 664. Middle East & Africa: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 665. Middle East & Africa: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 666. Middle East & Africa: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 667. Middle East & Africa: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 668. Middle East & Africa: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 669. Middle East & Africa: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 670. Middle East & Africa: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 671. Middle East & Africa: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 672. Middle East & Africa: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 673. Middle East & Africa: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 674. Middle East & Africa: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 675. Middle East & Africa: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 676. Middle East & Africa: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 677. Saudi Arabia: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 678. Saudi Arabia: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 679. Saudi Arabia: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 680. Saudi Arabia: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 681. Saudi Arabia: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 682. Saudi Arabia: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 683. Saudi Arabia: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 684. Saudi Arabia: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 685. Saudi Arabia: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 686. Saudi Arabia: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 687. Saudi Arabia: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 688. Saudi Arabia: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 689. Saudi Arabia: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 690. Saudi Arabia: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 691. Saudi Arabia: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 692. Saudi Arabia: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 693. Saudi Arabia: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 694. Saudi Arabia: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 695. Saudi Arabia: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 696. Saudi Arabia: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 697. Saudi Arabia: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 698. UAE: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 699. UAE: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 700. UAE: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 701. UAE: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 702. UAE: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 703. UAE: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 704. UAE: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 705. UAE: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 706. UAE: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 707. UAE: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 708. UAE: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 709. UAE: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 710. UAE: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 711. UAE: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 712. UAE: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 713. UAE: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 714. UAE: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 715. UAE: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 716. UAE: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 717. UAE: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 718. UAE: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 719. Israel: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 720. Israel: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 721. Israel: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 722. Israel: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 723. Israel: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 724. Israel: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 725. Israel: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 726. Israel: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 727. Israel: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 728. Israel: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 729. Israel: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 730. Israel: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 731. Israel: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 732. Israel: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 733. Israel: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 734. Israel: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 735. Israel: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 736. Israel: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 737. Israel: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 738. Israel: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 739. Israel: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 740. Turkey: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 741. Turkey: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 742. Turkey: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 743. Turkey: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 744. Turkey: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 745. Turkey: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 746. Turkey: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 747. Turkey: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 748. Turkey: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 749. Turkey: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 750. Turkey: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 751. Turkey: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 752. Turkey: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 753. Turkey: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 754. Turkey: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 755. Turkey: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 756. Turkey: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 757. Turkey: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 758. Turkey: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 759. Turkey: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 760. Turkey: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 761. South Africa: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 762. South Africa: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 763. South Africa: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 764. South Africa: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 765. South Africa: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 766. South Africa: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 767. South Africa: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 768. South Africa: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 769. South Africa: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 770. South Africa: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 771. South Africa: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 772. South Africa: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 773. South Africa: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 774. South Africa: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 775. South Africa: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 776. South Africa: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 777. South Africa: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 778. South Africa: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 779. South Africa: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 780. South Africa: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 781. South Africa: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 782. Egypt: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 783. Egypt: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 784. Egypt: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 785. Egypt: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 786. Egypt: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 787. Egypt: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 788. Egypt: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 789. Egypt: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 790. Egypt: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 791. Egypt: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 792. Egypt: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 793. Egypt: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 794. Egypt: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 795. Egypt: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 796. Egypt: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 797. Egypt: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 798. Egypt: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 799. Egypt: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 800. Egypt: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 801. Egypt: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 802. Egypt: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 803. Rest of Middle East & Africa: Acute Myeloid Leukemia Market, by Therapy Class, 2024-2036 (USD Million)
Table 804. Rest of Middle East & Africa: Acute Myeloid Leukemia Market for Targeted Therapy, by Type, 2024-2036 (USD Million)
Table 805. Rest of Middle East & Africa: Acute Myeloid Leukemia Market for Hypomethylating Agents, by Type, 2024-2036 (USD Million)
Table 806. Rest of Middle East & Africa: Acute Myeloid Leukemia Market for Chemotherapy, by Type, 2024-2036 (USD Million)
Table 807. Rest of Middle East & Africa: Acute Myeloid Leukemia Market for Immunotherapy & Antibody-Drug Conjugates, by Type, 2024-2036 (USD Million)
Table 808. Rest of Middle East & Africa: Acute Myeloid Leukemia Market for Cell & Gene Therapy, by Type, 2024-2036 (USD Million)
Table 809. Rest of Middle East & Africa: Acute Myeloid Leukemia Market, by Mutation Target, 2024-2036 (USD Million)
Table 810. Rest of Middle East & Africa: Acute Myeloid Leukemia Market for FLT3-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 811. Rest of Middle East & Africa: Acute Myeloid Leukemia Market for IDH-Mutated Disease, by Type, 2024-2036 (USD Million)
Table 812. Rest of Middle East & Africa: Acute Myeloid Leukemia Market, by Line of Therapy, 2024-2036 (USD Million)
Table 813. Rest of Middle East & Africa: Acute Myeloid Leukemia Market for Frontline Induction & Consolidation, by Type, 2024-2036 (USD Million)
Table 814. Rest of Middle East & Africa: Acute Myeloid Leukemia Market for Maintenance Therapy, by Type, 2024-2036 (USD Million)
Table 815. Rest of Middle East & Africa: Acute Myeloid Leukemia Market for Relapsed or Refractory Therapy, by Type, 2024-2036 (USD Million)
Table 816. Rest of Middle East & Africa: Acute Myeloid Leukemia Market, by Patient Fitness, 2024-2036 (USD Million)
Table 817. Rest of Middle East & Africa: Acute Myeloid Leukemia Market for Patients Ineligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 818. Rest of Middle East & Africa: Acute Myeloid Leukemia Market for Patients Eligible for Intensive Chemotherapy, by Type, 2024-2036 (USD Million)
Table 819. Rest of Middle East & Africa: Acute Myeloid Leukemia Market, by Route of Administration, 2024-2036 (USD Million)
Table 820. Rest of Middle East & Africa: Acute Myeloid Leukemia Market for Oral, by Type, 2024-2036 (USD Million)
Table 821. Rest of Middle East & Africa: Acute Myeloid Leukemia Market for Intravenous, by Type, 2024-2036 (USD Million)
Table 822. Rest of Middle East & Africa: Acute Myeloid Leukemia Market, by Treatment Setting, 2024-2036 (USD Million)
Table 823. Rest of Middle East & Africa: Acute Myeloid Leukemia Market, by End User, 2024-2036 (USD Million)
Table 824. Acute Myeloid Leukemia Market: Key Growth Strategies Adopted by Leading Players (2024-2026)
Table 825. Acute Myeloid Leukemia Market: Strategic Developments, by Company (2024-2026)
Table 826. Acute Myeloid Leukemia Market: Competitive Benchmarking
Table 827. Acute Myeloid Leukemia Market: Market Share/Ranking Analysis, by Key Player (2025)
Table 828. AbbVie Inc.: Product Portfolio
Table 829. AbbVie Inc.: Strategic Developments
Table 830. F. Hoffmann-La Roche Ltd: Product Portfolio
Table 831. F. Hoffmann-La Roche Ltd: Strategic Developments
Table 832. Astellas Pharma Inc.: Product Portfolio
Table 833. Astellas Pharma Inc.: Strategic Developments
Table 834. Novartis AG: Product Portfolio
Table 835. Novartis AG: Strategic Developments
Table 836. Daiichi Sankyo Company, Limited: Product Portfolio
Table 837. Daiichi Sankyo Company, Limited: Strategic Developments
Table 838. Servier Laboratories: Product Portfolio
Table 839. Servier Laboratories: Strategic Developments
Table 840. Bristol-Myers Squibb Company: Product Portfolio
Table 841. Bristol-Myers Squibb Company: Strategic Developments
Table 842. Pfizer Inc.: Product Portfolio
Table 843. Pfizer Inc.: Strategic Developments
Table 844. Jazz Pharmaceuticals plc: Product Portfolio
Table 845. Jazz Pharmaceuticals plc: Strategic Developments
Table 846. Syndax Pharmaceuticals, Inc.: Product Portfolio
Table 847. Syndax Pharmaceuticals, Inc.: Strategic Developments
Table 848. Kura Oncology, Inc.: Product Portfolio
Table 849. Kura Oncology, Inc.: Strategic Developments
Table 850. Kyowa Kirin Co., Ltd.: Product Portfolio
Table 851. Kyowa Kirin Co., Ltd.: Strategic Developments
Table 852. Otsuka Pharmaceutical Co., Ltd.: Product Portfolio
Table 853. Otsuka Pharmaceutical Co., Ltd.: Strategic Developments
Table 854. Taiho Pharmaceutical Co., Ltd.: Product Portfolio
Table 855. Taiho Pharmaceutical Co., Ltd.: Strategic Developments
Table 856. Rigel Pharmaceuticals, Inc.: Product Portfolio
Table 857. Rigel Pharmaceuticals, Inc.: Strategic Developments
Table 858. Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 859. Teva Pharmaceutical Industries Ltd.: Strategic Developments
Table 860. Sandoz Group AG: Product Portfolio
Table 861. Sandoz Group AG: Strategic Developments
Table 862. Dr. Reddy's Laboratories Ltd.: Product Portfolio
Table 863. Dr. Reddy's Laboratories Ltd.: Strategic Developments
Table 864. Hikma Pharmaceuticals PLC: Product Portfolio
Table 865. Hikma Pharmaceuticals PLC: Strategic Developments
Table 866. Johnson & Johnson: Product Portfolio
Table 867. Johnson & Johnson: Strategic Developments
Table 868. Sumitomo Pharma Co., Ltd.: Product Portfolio
Table 869. Sumitomo Pharma Co., Ltd.: Strategic Developments
Table 870. Aptose Biosciences Inc.: Product Portfolio
Table 871. Aptose Biosciences Inc.: Strategic Developments
Table 872. Immune-Onc Therapeutics, Inc.: Product Portfolio
Table 873. Immune-Onc Therapeutics, Inc.: Strategic Developments
Table 874. Available Customization Options
Table 875. Available Related Reports
LIST OF FIGURES
Figure 1. Research Process
Figure 2. Key Secondary Sources
Figure 3. Primary Research Techniques
Figure 4. Key Executives Interviewed
Figure 5. Breakdown of Primary Interviews (Supply-Side & Demand-Side)
Figure 6. Market Sizing and Growth Forecast Approach
Figure 7. Executive Summary: Global Acute Myeloid Leukemia Market Size, 2024-2036 (USD Million)
Figure 8. Executive Summary: Global Acute Myeloid Leukemia Market, by Therapy Class, 2026 vs. 2036 (USD Million)
Figure 9. Executive Summary: Global Acute Myeloid Leukemia Market, by Mutation Target, 2026 vs. 2036 (USD Million)
Figure 10. Executive Summary: Global Acute Myeloid Leukemia Market, by Line of Therapy, 2026 vs. 2036 (USD Million)
Figure 11. Executive Summary: Global Acute Myeloid Leukemia Market, by Patient Fitness, 2026 vs. 2036 (USD Million)
Figure 12. Executive Summary: Global Acute Myeloid Leukemia Market, by Route of Administration, 2026 vs. 2036 (USD Million)
Figure 13. Executive Summary: Global Acute Myeloid Leukemia Market, by Treatment Setting, 2026 vs. 2036 (USD Million)
Figure 14. Executive Summary: Global Acute Myeloid Leukemia Market, by End User, 2026 vs. 2036 (USD Million)
Figure 15. Executive Summary: Global Acute Myeloid Leukemia Market, by Region, 2026 vs. 2036 (USD Million)
Figure 16. Executive Summary: Competitive Landscape of the Acute Myeloid Leukemia Market
Figure 17. Factors Impacting the Growth of the Acute Myeloid Leukemia Market
Figure 18. Acute Myeloid Leukemia Market Ecosystem
Figure 19. AML Treatment Pathway: Intensive and Lower-Intensity Induction, Transplant, Maintenance and Relapse
Figure 20. Molecular Testing and MRD Workflow in AML
Figure 21. Value Chain Analysis: Acute Myeloid Leukemia Market
Figure 22. Global Acute Myeloid Leukemia Market, by Therapy Class, 2026 vs. 2036 (USD Million)
Figure 23. Global Acute Myeloid Leukemia Market, by Mutation Target, 2026 vs. 2036 (USD Million)
Figure 24. Global Acute Myeloid Leukemia Market, by Line of Therapy, 2026 vs. 2036 (USD Million)
Figure 25. Global Acute Myeloid Leukemia Market, by Patient Fitness, 2026 vs. 2036 (USD Million)
Figure 26. Global Acute Myeloid Leukemia Market, by Route of Administration, 2026 vs. 2036 (USD Million)
Figure 27. Global Acute Myeloid Leukemia Market, by Treatment Setting, 2026 vs. 2036 (USD Million)
Figure 28. Global Acute Myeloid Leukemia Market, by End User, 2026 vs. 2036 (USD Million)
Figure 29. Global Acute Myeloid Leukemia Market, by Region, 2026 vs. 2036 (USD Million)
Figure 30. North America: Acute Myeloid Leukemia Market Snapshot
Figure 31. Europe: Acute Myeloid Leukemia Market Snapshot
Figure 32. Asia-Pacific: Acute Myeloid Leukemia Market Snapshot
Figure 33. Latin America: Acute Myeloid Leukemia Market Snapshot
Figure 34. Middle East & Africa: Acute Myeloid Leukemia Market Snapshot
Figure 35. Key Growth Strategies Adopted by Leading Players in the Acute Myeloid Leukemia Market (2024-2026)
Figure 36. Acute Myeloid Leukemia Market: Competitive Dashboard
Figure 37. Acute Myeloid Leukemia Market Share/Ranking Analysis, by Key Player (2025)
Figure 38. AbbVie Inc.: SWOT Analysis
Figure 39. F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 40. Astellas Pharma Inc.: SWOT Analysis
Figure 41. Novartis AG: SWOT Analysis
Figure 42. Daiichi Sankyo Company, Limited: SWOT Analysis
Figure 43. Servier Laboratories: SWOT Analysis
Figure 44. Bristol-Myers Squibb Company: SWOT Analysis
Figure 45. Pfizer Inc.: SWOT Analysis
Figure 46. Jazz Pharmaceuticals plc: SWOT Analysis
Figure 47. Syndax Pharmaceuticals, Inc.: SWOT Analysis
Figure 48. Kura Oncology, Inc.: SWOT Analysis
Figure 49. Kyowa Kirin Co., Ltd.: SWOT Analysis
Figure 50. Otsuka Pharmaceutical Co., Ltd.: SWOT Analysis
Figure 51. Taiho Pharmaceutical Co., Ltd.: SWOT Analysis
Figure 52. Rigel Pharmaceuticals, Inc.: SWOT Analysis
Figure 53. Teva Pharmaceutical Industries Ltd.: SWOT Analysis
Figure 54. Sandoz Group AG: SWOT Analysis
Figure 55. Dr. Reddy's Laboratories Ltd.: SWOT Analysis
Figure 56. Hikma Pharmaceuticals PLC: SWOT Analysis
Figure 57. Johnson & Johnson: SWOT Analysis
Figure 58. Sumitomo Pharma Co., Ltd.: SWOT Analysis
Figure 59. Aptose Biosciences Inc.: SWOT Analysis
Figure 60. Immune-Onc Therapeutics, Inc.: SWOT Analysis
Figure 2. Key Secondary Sources
Figure 3. Primary Research Techniques
Figure 4. Key Executives Interviewed
Figure 5. Breakdown of Primary Interviews (Supply-Side & Demand-Side)
Figure 6. Market Sizing and Growth Forecast Approach
Figure 7. Executive Summary: Global Acute Myeloid Leukemia Market Size, 2024-2036 (USD Million)
Figure 8. Executive Summary: Global Acute Myeloid Leukemia Market, by Therapy Class, 2026 vs. 2036 (USD Million)
Figure 9. Executive Summary: Global Acute Myeloid Leukemia Market, by Mutation Target, 2026 vs. 2036 (USD Million)
Figure 10. Executive Summary: Global Acute Myeloid Leukemia Market, by Line of Therapy, 2026 vs. 2036 (USD Million)
Figure 11. Executive Summary: Global Acute Myeloid Leukemia Market, by Patient Fitness, 2026 vs. 2036 (USD Million)
Figure 12. Executive Summary: Global Acute Myeloid Leukemia Market, by Route of Administration, 2026 vs. 2036 (USD Million)
Figure 13. Executive Summary: Global Acute Myeloid Leukemia Market, by Treatment Setting, 2026 vs. 2036 (USD Million)
Figure 14. Executive Summary: Global Acute Myeloid Leukemia Market, by End User, 2026 vs. 2036 (USD Million)
Figure 15. Executive Summary: Global Acute Myeloid Leukemia Market, by Region, 2026 vs. 2036 (USD Million)
Figure 16. Executive Summary: Competitive Landscape of the Acute Myeloid Leukemia Market
Figure 17. Factors Impacting the Growth of the Acute Myeloid Leukemia Market
Figure 18. Acute Myeloid Leukemia Market Ecosystem
Figure 19. AML Treatment Pathway: Intensive and Lower-Intensity Induction, Transplant, Maintenance and Relapse
Figure 20. Molecular Testing and MRD Workflow in AML
Figure 21. Value Chain Analysis: Acute Myeloid Leukemia Market
Figure 22. Global Acute Myeloid Leukemia Market, by Therapy Class, 2026 vs. 2036 (USD Million)
Figure 23. Global Acute Myeloid Leukemia Market, by Mutation Target, 2026 vs. 2036 (USD Million)
Figure 24. Global Acute Myeloid Leukemia Market, by Line of Therapy, 2026 vs. 2036 (USD Million)
Figure 25. Global Acute Myeloid Leukemia Market, by Patient Fitness, 2026 vs. 2036 (USD Million)
Figure 26. Global Acute Myeloid Leukemia Market, by Route of Administration, 2026 vs. 2036 (USD Million)
Figure 27. Global Acute Myeloid Leukemia Market, by Treatment Setting, 2026 vs. 2036 (USD Million)
Figure 28. Global Acute Myeloid Leukemia Market, by End User, 2026 vs. 2036 (USD Million)
Figure 29. Global Acute Myeloid Leukemia Market, by Region, 2026 vs. 2036 (USD Million)
Figure 30. North America: Acute Myeloid Leukemia Market Snapshot
Figure 31. Europe: Acute Myeloid Leukemia Market Snapshot
Figure 32. Asia-Pacific: Acute Myeloid Leukemia Market Snapshot
Figure 33. Latin America: Acute Myeloid Leukemia Market Snapshot
Figure 34. Middle East & Africa: Acute Myeloid Leukemia Market Snapshot
Figure 35. Key Growth Strategies Adopted by Leading Players in the Acute Myeloid Leukemia Market (2024-2026)
Figure 36. Acute Myeloid Leukemia Market: Competitive Dashboard
Figure 37. Acute Myeloid Leukemia Market Share/Ranking Analysis, by Key Player (2025)
Figure 38. AbbVie Inc.: SWOT Analysis
Figure 39. F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 40. Astellas Pharma Inc.: SWOT Analysis
Figure 41. Novartis AG: SWOT Analysis
Figure 42. Daiichi Sankyo Company, Limited: SWOT Analysis
Figure 43. Servier Laboratories: SWOT Analysis
Figure 44. Bristol-Myers Squibb Company: SWOT Analysis
Figure 45. Pfizer Inc.: SWOT Analysis
Figure 46. Jazz Pharmaceuticals plc: SWOT Analysis
Figure 47. Syndax Pharmaceuticals, Inc.: SWOT Analysis
Figure 48. Kura Oncology, Inc.: SWOT Analysis
Figure 49. Kyowa Kirin Co., Ltd.: SWOT Analysis
Figure 50. Otsuka Pharmaceutical Co., Ltd.: SWOT Analysis
Figure 51. Taiho Pharmaceutical Co., Ltd.: SWOT Analysis
Figure 52. Rigel Pharmaceuticals, Inc.: SWOT Analysis
Figure 53. Teva Pharmaceutical Industries Ltd.: SWOT Analysis
Figure 54. Sandoz Group AG: SWOT Analysis
Figure 55. Dr. Reddy's Laboratories Ltd.: SWOT Analysis
Figure 56. Hikma Pharmaceuticals PLC: SWOT Analysis
Figure 57. Johnson & Johnson: SWOT Analysis
Figure 58. Sumitomo Pharma Co., Ltd.: SWOT Analysis
Figure 59. Aptose Biosciences Inc.: SWOT Analysis
Figure 60. Immune-Onc Therapeutics, Inc.: SWOT Analysis
Companies Mentioned
- AbbVie Inc.
- F. Hoffmann-La Roche Ltd
- Astellas Pharma Inc.
- Novartis AG
- Daiichi Sankyo Company, Limited
- Servier Laboratories
- Bristol-Myers Squibb Company
- Pfizer Inc.
- Jazz Pharmaceuticals plc
- Syndax Pharmaceuticals, Inc.
- Kura Oncology, Inc.
- Kyowa Kirin Co., Ltd.
- Otsuka Pharmaceutical Co., Ltd.
- Taiho Pharmaceutical Co., Ltd.
- Rigel Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
- Sandoz Group AG
- Dr. Reddy's Laboratories Ltd.
- Hikma Pharmaceuticals PLC
- Johnson & Johnson
- Sumitomo Pharma Co., Ltd.
- Aptose Biosciences Inc.
- Immune-Onc Therapeutics, Inc.
